{
    "id": 64,
    "premise": "none",
    "hypothesis": "If patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation.",
    "label": "entailment",
    "explanation": "Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.\nTreatment with alpelisib\u2013fulvestrant prolonged progression-free survival among patients with\u00a0PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously.\u00a0\nPatient is likely less sensitive to chemotherapy.",
    "results": {
        "semantic validity": false,
        "premise": null,
        "hypothesis": "If patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation.",
        "history explanation": [
            "0 iteration: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.\nTreatment with alpelisib\u2013fulvestrant prolonged progression-free survival among patients with\u00a0PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously.\u00a0\nPatient is likely less sensitive to chemotherapy.",
            "1 iteration: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.\nTreatment with alpelisib\u2013fulvestrant is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it targets the PIK3CA mutation and prolongs progression-free survival.\nPatient is likely less sensitive to chemotherapy.",
            "2 iteration: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.\nTreatment with alpelisib\u2013fulvestrant is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it targets the PIK3CA mutation and prolongs progression-free survival.\nPatient is likely less sensitive to chemotherapy.",
            "3 iteration: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.\nTreatment with alpelisib\u2013fulvestrant directly targets the PIK3CA mutation and is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it prolongs progression-free survival.\nPatient is likely less sensitive to chemotherapy.",
            "4 iteration: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.\nTreatment with alpelisib\u2013fulvestrant directly targets the PIK3CA mutation and is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it prolongs progression-free survival.\nPatients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer may benefit from treatment with alpelisib-fulvestrant.\nPatient is likely less sensitive to chemotherapy.",
            "5 iteration: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.\nTreatment with alpelisib\u2013fulvestrant directly targets the PIK3CA mutation and is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it prolongs progression-free survival.\nPatients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer may benefit from treatment with alpelisib-fulvestrant.\nPatient is likely less sensitive to chemotherapy.",
            "6 iteration: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.\nTreatment with alpelisib\u2013fulvestrant directly targets the PIK3CA mutation and is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it prolongs progression-free survival.\nPatients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer may benefit from treatment with alpelisib-fulvestrant, which targets the PIK3CA mutation.\nPatient is likely less sensitive to chemotherapy.",
            "7 iteration: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.\nTreatment with alpelisib\u2013fulvestrant directly targets the PIK3CA mutation and is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it prolongs progression-free survival.\nPatients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer may benefit from treatment with alpelisib-fulvestrant, which targets the PIK3CA mutation.\nPatient is likely less sensitive to chemotherapy.",
            "8 iteration: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.\nTreatment with alpelisib\u2013fulvestrant directly targets the PIK3CA mutation and is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it prolongs progression-free survival.\nPatients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer benefit from treatment with alpelisib-fulvestrant, which targets the PIK3CA mutation and improves outcomes.\nPatient is likely less sensitive to chemotherapy.",
            "9 iteration: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.\nTreatment with alpelisib\u2013fulvestrant directly targets the PIK3CA mutation and is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it prolongs progression-free survival.\nPatients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer benefit from treatment with alpelisib-fulvestrant, which targets the PIK3CA mutation and improves outcomes.\nPatient is likely less sensitive to chemotherapy.\nPatients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who have previously received endocrine therapy benefit from treatment with alpelisib-fulvestrant, as it targets the PIK3CA mutation and improves outcomes.",
            "10 iteration: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival.\nTreatment with alpelisib\u2013fulvestrant directly targets the PIK3CA mutation and is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it prolongs progression-free survival.\nPatients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer benefit from treatment with alpelisib-fulvestrant, which targets the PIK3CA mutation and improves outcomes.\nPatient is likely less sensitive to chemotherapy.\nPatients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who have previously received endocrine therapy benefit from treatment with alpelisib-fulvestrant, as it targets the PIK3CA mutation and improves outcomes.\nTreatment with alpelisib-fulvestrant is specifically beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, as it directly targets the PIK3CA mutation and improves outcomes for those who have previously received endocrine therapy."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: False",
            "7 iteration: False",
            "8 iteration: False",
            "9 iteration: False",
            "10 iteration: False"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': True, 'error code': '(* Explanation 2 provides a scenario where treatment with alpelisib\u2013fulvestrant is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. *)\\n(* We can use this to infer that such patients may benefit from the treatment. *)\\nfrom explanation_2 have \"\u2203x y z w e1 e2. Treatment x \u2227 AlpelisibFulvestrant x \u2227 ProgressionFreeSurvival y \u2227 Patients z \u2227 PIK3CAMutated z \u2227 HRPositive z \u2227 HER2Negative z \u2227 AdvancedBreastCancer z \u2227 (Prolonged e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Among e1 z) \u2227 (EndocrineTherapy w \u2227 Received e2 \u2227 Agent e2 z \u2227 Patient e2 w \u2227 Previously e2)\" sledgehammer', 'solving time': 103.85468459129333, 'proof tactics': [], 'code': 'theory clinical_64_0\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  PI3KAKTPathway :: \"entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  AlpelisibFulvestrant :: \"entity \u21d2 bool\"\\n  ProgressionFreeSurvival :: \"entity \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  PIK3CAMutated :: \"entity \u21d2 bool\"\\n  HRPositive :: \"entity \u21d2 bool\"\\n  HER2Negative :: \"entity \u21d2 bool\"\\n  AdvancedBreastCancer :: \"entity \u21d2 bool\"\\n  Prolonged :: \"event \u21d2 bool\"\\n  Among :: \"event \u21d2 entity \u21d2 bool\"\\n  EndocrineTherapy :: \"entity \u21d2 bool\"\\n  Received :: \"event \u21d2 bool\"\\n  Previously :: \"event \u21d2 bool\"\\n  LessSensitiveTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  Chemotherapy :: \"entity \u21d2 bool\"\\n  PatientEntity :: \"entity \u21d2 bool\"  (* Renamed to avoid confusion with Patient event *)\\n  Benefit :: \"event \u21d2 bool\"\\n  From :: \"event \u21d2 entity \u21d2 bool\"\\n  PIK3CAMutation :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 Mutations y \u2227 PI3KAKTPathway y \u2227 Proliferation z \u2227 Survival z \u2227 (Target e1 \u2227 Agent e1 x \u2227 Patient e1 y) \u2227 (Inhibit e2 \u2227 Agent e2 x \u2227 Patient e2 z)\"\\n\\n(* Explanation 2: Treatment with alpelisib\u2013fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2. Treatment x \u2227 AlpelisibFulvestrant x \u2227 ProgressionFreeSurvival y \u2227 Patients z \u2227 PIK3CAMutated z \u2227 HRPositive z \u2227 HER2Negative z \u2227 AdvancedBreastCancer z \u2227 (Prolonged e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Among e1 z) \u2227 (EndocrineTherapy w \u2227 Received e2 \u2227 Agent e2 z \u2227 Patient e2 w \u2227 Previously e2)\"\\n\\n(* Explanation 3: Patient is likely less sensitive to chemotherapy. *)\\naxiomatization where\\n  explanation_3: \"\u2200x y. PatientEntity x \u2227 Chemotherapy y \u27f6 LessSensitiveTo x y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"PatientEntity x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1\"\\n  (* Hypothesis: If patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n  shows \"\u2200x y z e1 e2. (PatientEntity x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1) \u27f6 (Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 From e2 z \u2227 Target e2 \u2227 PIK3CAMutation z)\"\\nproof -\\n  (* From the premise, we have information about the patient having previously received endocrine therapy. *)\\n  from asm have \"PatientEntity x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1\" <ATP>\\n  \\n  (* Explanation 2 provides a scenario where treatment with alpelisib\u2013fulvestrant is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. *)\\n  (* We can use this to infer that such patients may benefit from the treatment. *)\\n  from explanation_2 have \"\u2203x y z w e1 e2. Treatment x \u2227 AlpelisibFulvestrant x \u2227 ProgressionFreeSurvival y \u2227 Patients z \u2227 PIK3CAMutated z \u2227 HRPositive z \u2227 HER2Negative z \u2227 AdvancedBreastCancer z \u2227 (Prolonged e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Among e1 z) \u2227 (EndocrineTherapy w \u2227 Received e2 \u2227 Agent e2 z \u2227 Patient e2 w \u2227 Previously e2)\" <ATP>\\n  \\n  (* Since the patient has previously received endocrine therapy, they fit the criteria for benefiting from alpelisib-fulvestrant treatment. *)\\n  then have \"Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 From e2 z \u2227 Target e2 \u2227 PIK3CAMutation z\" <ATP>\\n  \\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: using a kinase inhibitor (from Explanatory Sentence 1)\\nB: target mutations in the PI3K/AKT pathway (from Explanatory Sentence 1)\\nC: inhibit proliferation and survival (from Explanatory Sentence 1)\\nD: treatment with alpelisib\u2013fulvestrant (from Explanatory Sentence 2)\\nE: prolonged progression-free survival (from Explanatory Sentence 2)\\nF: patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously (from Explanatory Sentence 2)\\nG: patient is less sensitive to chemotherapy (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, And(B, C))\\nImplies(using a kinase inhibitor, B & C)\\n--------\\nImplies(And(D, F), E)\\nImplies(D & F, prolonged progression-free survival)\\n--------\\nG\\npatient is less sensitive to chemotherapy\\n--------\\n\\nDerived Implications:\\nImplies(D, G)\\nImplies(treatment with alpelisib\u2013fulvestrant, patient is less sensitive to chemotherapy)\\n--------\\nImplies(Not(G), Not(E))\\nImplies(Not(patient is less sensitive to chemotherapy), Not(prolonged progression-free survival))\\n--------\\nImplies(Not(F), G)\\nImplies(Not(patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously), patient is less sensitive to chemotherapy)\\n--------\\nImplies(Not(A), G)\\nImplies(Not(using a kinase inhibitor), patient is less sensitive to chemotherapy)\\n--------\\nImplies(Not(G), D)\\nImplies(Not(patient is less sensitive to chemotherapy), treatment with alpelisib\u2013fulvestrant)\\n--------\\nImplies(Not(C), G)\\nImplies(Not(inhibit proliferation and survival), patient is less sensitive to chemotherapy)\\n--------\\nImplies(E, G)\\nImplies(prolonged progression-free survival, patient is less sensitive to chemotherapy)\\n--------\\nImplies(Not(G), Not(A))\\nImplies(Not(patient is less sensitive to chemotherapy), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(G), Not(B))\\nImplies(Not(patient is less sensitive to chemotherapy), Not(target mutations in the PI3K/AKT pathway))\\n--------\\nImplies(B, G)\\nImplies(target mutations in the PI3K/AKT pathway, patient is less sensitive to chemotherapy)\\n--------\\nImplies(A, G)\\nImplies(using a kinase inhibitor, patient is less sensitive to chemotherapy)\\n--------\\nImplies(Not(E), G)\\nImplies(Not(prolonged progression-free survival), patient is less sensitive to chemotherapy)\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(target mutations in the PI3K/AKT pathway), Not(using a kinase inhibitor))\\n--------\\nImplies(A, B)\\nImplies(using a kinase inhibitor, target mutations in the PI3K/AKT pathway)\\n--------\\nImplies(Not(G), Not(D))\\nImplies(Not(patient is less sensitive to chemotherapy), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(A, C)\\nImplies(using a kinase inhibitor, inhibit proliferation and survival)\\n--------\\nImplies(Not(G), Not(C))\\nImplies(Not(patient is less sensitive to chemotherapy), Not(inhibit proliferation and survival))\\n--------\\nImplies(Not(G), B)\\nImplies(Not(patient is less sensitive to chemotherapy), target mutations in the PI3K/AKT pathway)\\n--------\\nImplies(Not(D), G)\\nImplies(Not(treatment with alpelisib\u2013fulvestrant), patient is less sensitive to chemotherapy)\\n--------\\nImplies(Not(G), C)\\nImplies(Not(patient is less sensitive to chemotherapy), inhibit proliferation and survival)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(inhibit proliferation and survival), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(G), A)\\nImplies(Not(patient is less sensitive to chemotherapy), using a kinase inhibitor)\\n--------\\nImplies(C, G)\\nImplies(inhibit proliferation and survival, patient is less sensitive to chemotherapy)\\n--------\\nImplies(Not(G), Not(F))\\nImplies(Not(patient is less sensitive to chemotherapy), Not(patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously))\\n--------\\nImplies(Not(B), G)\\nImplies(Not(target mutations in the PI3K/AKT pathway), patient is less sensitive to chemotherapy)\\n--------\\nImplies(Not(G), E)\\nImplies(Not(patient is less sensitive to chemotherapy), prolonged progression-free survival)\\n--------\\nImplies(Not(G), F)\\nImplies(Not(patient is less sensitive to chemotherapy), patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(F, G)\\nImplies(patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is less sensitive to chemotherapy)\\n--------\\n'}",
            "1 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 10.949484825134277, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"bool\"\\n\\nType error in application: operator not of function type\\n\\nOperator:  Target e2 :: bool\\nOperand:   z :: entity\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_64_1\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  PI3KAKTPathway :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  AlpelisibFulvestrant :: \"entity \u21d2 bool\"\\n  PIK3CAMutated :: \"entity \u21d2 bool\"\\n  HRPositive :: \"entity \u21d2 bool\"\\n  HER2Negative :: \"entity \u21d2 bool\"\\n  AdvancedBreastCancer :: \"entity \u21d2 bool\"\\n  EndocrineTherapy :: \"entity \u21d2 bool\"\\n  Received :: \"event \u21d2 bool\"\\n  Previously :: \"event \u21d2 bool\"\\n  Beneficial :: \"entity \u21d2 entity \u21d2 bool\"\\n  PIK3CAMutation :: \"entity \u21d2 bool\"\\n  Prolong :: \"event \u21d2 bool\"\\n  ProgressionFreeSurvival :: \"entity \u21d2 bool\"\\n  LikelyLessSensitive :: \"entity \u21d2 entity \u21d2 bool\"\\n  Chemotherapy :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  From :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 Mutations y \u2227 PI3KAKTPathway z \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Inhibit e2 \u2227 Agent e2 x \u2227 Proliferation y \u2227 Survival y\"\\n\\n(* Explanation 2: Treatment with alpelisib\u2013fulvestrant is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it targets the PIK3CA mutation and prolongs progression-free survival. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2 e3. Treatment x \u2227 AlpelisibFulvestrant x \u2227 Agent e1 y \u2227 PIK3CAMutated y \u2227 HRPositive y \u2227 HER2Negative y \u2227 AdvancedBreastCancer y \u2227 EndocrineTherapy z \u2227 Received e1 \u2227 Agent e1 y \u2227 Patient e1 z \u2227 Previously e1 \u2227 Beneficial x y \u2227 PIK3CAMutation w \u2227 Target e2 \u2227 Agent e2 x \u2227 Patient e2 w \u2227 Prolong e3 \u2227 Agent e3 x \u2227 ProgressionFreeSurvival w\"\\n\\n(* Explanation 3: Patient is likely less sensitive to chemotherapy. *)\\naxiomatization where\\n  explanation_3: \"\u2200x y e. Agent e x \u2227 Chemotherapy y \u27f6 LikelyLessSensitive x y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Agent e x \u2227 EndocrineTherapy y \u2227 Received e \u2227 Agent e x \u2227 Patient e y \u2227 Previously e\"\\n  (* Hypothesis: If patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation *)\\n  shows \"\u2203x y z e1 e2. (\u2203e. Agent e x \u2227 EndocrineTherapy y \u2227 Received e \u2227 Agent e x \u2227 Patient e y \u2227 Previously e) \u27f6 (Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 From e2 z \u2227 AlpelisibFulvestrant z \u2227 Target e2 z)\"\\nproof -\\n  (* From the premise, we have the known information about the patient having previously received endocrine therapy. *)\\n  from asm have \"Agent e x \u2227 EndocrineTherapy y \u2227 Received e \u2227 Agent e x \u2227 Patient e y \u2227 Previously e\" <ATP>\\n  (* Explanation 2 provides that treatment with alpelisib\u2013fulvestrant is beneficial for patients who had received endocrine therapy previously. *)\\n  (* There is a logical relation Implies(D, E), Implies(treatment with alpelisib\u2013fulvestrant, beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously) *)\\n  (* We can infer that the patient may benefit from treatment with alpelisib-fulvestrant. *)\\n  then have \"\u2203x y z e1 e2. Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 From e2 z \u2227 AlpelisibFulvestrant z \u2227 Target e2 z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: using a kinase inhibitor (from Explanatory Sentence 1)\\nB: target mutations in the PI3K/AKT pathway (from Explanatory Sentence 1)\\nC: inhibit proliferation and survival (from Explanatory Sentence 1)\\nD: treatment with alpelisib\u2013fulvestrant (from Explanatory Sentence 2)\\nE: beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously (from Explanatory Sentence 2)\\nF: targets the PIK3CA mutation (from Explanatory Sentence 2)\\nG: prolongs progression-free survival (from Explanatory Sentence 2)\\nH: patient is likely less sensitive to chemotherapy (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, And(B, C))\\nImplies(using a kinase inhibitor, B & C)\\n--------\\nImplies(D, And(E, F, G))\\nImplies(treatment with alpelisib\u2013fulvestrant, E & F & G)\\n--------\\nH\\npatient is likely less sensitive to chemotherapy\\n--------\\n\\nDerived Implications:\\nImplies(D, G)\\nImplies(treatment with alpelisib\u2013fulvestrant, prolongs progression-free survival)\\n--------\\nImplies(Not(H), F)\\nImplies(Not(patient is likely less sensitive to chemotherapy), targets the PIK3CA mutation)\\n--------\\nImplies(Not(F), Not(D))\\nImplies(Not(targets the PIK3CA mutation), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(Not(D), H)\\nImplies(Not(treatment with alpelisib\u2013fulvestrant), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(H), D)\\nImplies(Not(patient is likely less sensitive to chemotherapy), treatment with alpelisib\u2013fulvestrant)\\n--------\\nImplies(Not(H), Not(E))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously))\\n--------\\nImplies(C, H)\\nImplies(inhibit proliferation and survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(H), Not(A))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(B), H)\\nImplies(Not(target mutations in the PI3K/AKT pathway), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(H), Not(B))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(target mutations in the PI3K/AKT pathway))\\n--------\\nImplies(Not(H), Not(G))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(prolongs progression-free survival))\\n--------\\nImplies(Not(E), Not(D))\\nImplies(Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(D, F)\\nImplies(treatment with alpelisib\u2013fulvestrant, targets the PIK3CA mutation)\\n--------\\nImplies(D, E)\\nImplies(treatment with alpelisib\u2013fulvestrant, beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(F, H)\\nImplies(targets the PIK3CA mutation, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(target mutations in the PI3K/AKT pathway), Not(using a kinase inhibitor))\\n--------\\nImplies(D, H)\\nImplies(treatment with alpelisib\u2013fulvestrant, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(A, B)\\nImplies(using a kinase inhibitor, target mutations in the PI3K/AKT pathway)\\n--------\\nImplies(Not(G), Not(D))\\nImplies(Not(prolongs progression-free survival), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(Not(F), H)\\nImplies(Not(targets the PIK3CA mutation), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(A, C)\\nImplies(using a kinase inhibitor, inhibit proliferation and survival)\\n--------\\nImplies(Not(C), H)\\nImplies(Not(inhibit proliferation and survival), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(H), Not(D))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(E, H)\\nImplies(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(A), H)\\nImplies(Not(using a kinase inhibitor), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(H), G)\\nImplies(Not(patient is likely less sensitive to chemotherapy), prolongs progression-free survival)\\n--------\\nImplies(G, H)\\nImplies(prolongs progression-free survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(B, H)\\nImplies(target mutations in the PI3K/AKT pathway, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(inhibit proliferation and survival), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(H), Not(C))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(inhibit proliferation and survival))\\n--------\\nImplies(Not(H), B)\\nImplies(Not(patient is likely less sensitive to chemotherapy), target mutations in the PI3K/AKT pathway)\\n--------\\nImplies(Not(H), C)\\nImplies(Not(patient is likely less sensitive to chemotherapy), inhibit proliferation and survival)\\n--------\\nImplies(Not(H), A)\\nImplies(Not(patient is likely less sensitive to chemotherapy), using a kinase inhibitor)\\n--------\\nImplies(Not(H), Not(F))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(targets the PIK3CA mutation))\\n--------\\nImplies(Not(E), H)\\nImplies(Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(A, H)\\nImplies(using a kinase inhibitor, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(H), E)\\nImplies(Not(patient is likely less sensitive to chemotherapy), beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(Not(G), H)\\nImplies(Not(prolongs progression-free survival), patient is likely less sensitive to chemotherapy)\\n--------\\n'}",
            "2 iteration: {'syntactic validity': True, 'error code': '(* Explanation 2 provides that treatment with alpelisib\u2013fulvestrant is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. *)\\n(* This implies that such patients may benefit from treatment with alpelisib-fulvestrant to target the PIK3CA mutation. *)\\n(* We can use the logical relation Implies(D, And(E, F, G)) to infer the benefit and targeting of PIK3CA mutation. *)\\nthen have \"Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 From e2 z \u2227 Target e2 \u2227 PIK3CAMutation z\" sledgehammer', 'solving time': 103.45953726768494, 'proof tactics': [], 'code': 'theory clinical_64_2\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  PI3KAKTPathway :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  PatientEvent :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  AlpelisibFulvestrant :: \"entity \u21d2 bool\"\\n  Beneficial :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  PIK3CAMutated :: \"entity \u21d2 bool\"\\n  HRPositive :: \"entity \u21d2 bool\"\\n  HER2Negative :: \"entity \u21d2 bool\"\\n  AdvancedBreastCancer :: \"entity \u21d2 bool\"\\n  EndocrineTherapy :: \"entity \u21d2 bool\"\\n  Received :: \"event \u21d2 bool\"\\n  Previously :: \"event \u21d2 bool\"\\n  PIK3CAMutation :: \"entity \u21d2 bool\"\\n  Prolong :: \"event \u21d2 bool\"\\n  ProgressionFreeSurvival :: \"entity \u21d2 bool\"\\n  LessSensitive :: \"entity \u21d2 entity \u21d2 bool\"\\n  Chemotherapy :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  From :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 Mutations y \u2227 PI3KAKTPathway z \u2227 Target e1 \u2227 Agent e1 x \u2227 PatientEvent e1 y \u2227 In y z \u2227 Inhibit e2 \u2227 Agent e2 x \u2227 Proliferation y \u2227 Survival y\"\\n\\n(* Explanation 2: Treatment with alpelisib\u2013fulvestrant is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it targets the PIK3CA mutation and prolongs progression-free survival. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2 e3. Treatment x \u2227 AlpelisibFulvestrant x \u2227 Beneficial x \u2227 Patient y \u2227 PIK3CAMutated y \u2227 HRPositive y \u2227 HER2Negative y \u2227 AdvancedBreastCancer y \u2227 EndocrineTherapy z \u2227 Received e1 \u2227 Agent e1 y \u2227 PatientEvent e1 z \u2227 Previously e1 \u2227 PIK3CAMutation w \u2227 Target e2 \u2227 Agent e2 x \u2227 PatientEvent e2 w \u2227 Prolong e3 \u2227 Agent e3 x \u2227 ProgressionFreeSurvival w\"\\n\\n(* Explanation 3: Patient is likely less sensitive to chemotherapy. *)\\naxiomatization where\\n  explanation_3: \"\u2200x y. Patient x \u2227 Chemotherapy y \u27f6 LessSensitive x y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 PatientEvent e1 y \u2227 Previously e1\"\\n  (* Hypothesis: If patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation *)\\n  shows \"\u2200x y z e1 e2. (Patient x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 PatientEvent e1 y \u2227 Previously e1) \u27f6 (Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 From e2 z \u2227 Target e2 \u2227 PIK3CAMutation z)\"\\nproof -\\n  (* From the premise, we have the known information about the patient and their previous endocrine therapy. *)\\n  from asm have \"Patient x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 PatientEvent e1 y \u2227 Previously e1\" <ATP>\\n  (* Explanation 2 provides that treatment with alpelisib\u2013fulvestrant is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. *)\\n  (* This implies that such patients may benefit from treatment with alpelisib-fulvestrant to target the PIK3CA mutation. *)\\n  (* We can use the logical relation Implies(D, And(E, F, G)) to infer the benefit and targeting of PIK3CA mutation. *)\\n  then have \"Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 From e2 z \u2227 Target e2 \u2227 PIK3CAMutation z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: using a kinase inhibitor (from Explanatory Sentence 1)\\nB: target mutations in the PI3K/AKT pathway (from Explanatory Sentence 1)\\nC: inhibit proliferation and survival (from Explanatory Sentence 1)\\nD: treatment with alpelisib\u2013fulvestrant (from Explanatory Sentence 2)\\nE: beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously (from Explanatory Sentence 2)\\nF: targets the PIK3CA mutation (from Explanatory Sentence 2)\\nG: prolongs progression-free survival (from Explanatory Sentence 2)\\nH: patient is likely less sensitive to chemotherapy (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, And(B, C))\\nImplies(using a kinase inhibitor, B & C)\\n--------\\nImplies(D, And(E, F, G))\\nImplies(treatment with alpelisib\u2013fulvestrant, E & F & G)\\n--------\\nH\\npatient is likely less sensitive to chemotherapy\\n--------\\n\\nDerived Implications:\\nImplies(D, G)\\nImplies(treatment with alpelisib\u2013fulvestrant, prolongs progression-free survival)\\n--------\\nImplies(Not(H), F)\\nImplies(Not(patient is likely less sensitive to chemotherapy), targets the PIK3CA mutation)\\n--------\\nImplies(Not(F), Not(D))\\nImplies(Not(targets the PIK3CA mutation), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(Not(D), H)\\nImplies(Not(treatment with alpelisib\u2013fulvestrant), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(H), D)\\nImplies(Not(patient is likely less sensitive to chemotherapy), treatment with alpelisib\u2013fulvestrant)\\n--------\\nImplies(Not(H), Not(E))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously))\\n--------\\nImplies(C, H)\\nImplies(inhibit proliferation and survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(H), Not(A))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(B), H)\\nImplies(Not(target mutations in the PI3K/AKT pathway), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(H), Not(B))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(target mutations in the PI3K/AKT pathway))\\n--------\\nImplies(Not(H), Not(G))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(prolongs progression-free survival))\\n--------\\nImplies(Not(E), Not(D))\\nImplies(Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(D, F)\\nImplies(treatment with alpelisib\u2013fulvestrant, targets the PIK3CA mutation)\\n--------\\nImplies(D, E)\\nImplies(treatment with alpelisib\u2013fulvestrant, beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(F, H)\\nImplies(targets the PIK3CA mutation, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(target mutations in the PI3K/AKT pathway), Not(using a kinase inhibitor))\\n--------\\nImplies(D, H)\\nImplies(treatment with alpelisib\u2013fulvestrant, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(A, B)\\nImplies(using a kinase inhibitor, target mutations in the PI3K/AKT pathway)\\n--------\\nImplies(Not(G), Not(D))\\nImplies(Not(prolongs progression-free survival), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(Not(F), H)\\nImplies(Not(targets the PIK3CA mutation), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(A, C)\\nImplies(using a kinase inhibitor, inhibit proliferation and survival)\\n--------\\nImplies(Not(C), H)\\nImplies(Not(inhibit proliferation and survival), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(H), Not(D))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(E, H)\\nImplies(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(A), H)\\nImplies(Not(using a kinase inhibitor), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(H), G)\\nImplies(Not(patient is likely less sensitive to chemotherapy), prolongs progression-free survival)\\n--------\\nImplies(G, H)\\nImplies(prolongs progression-free survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(B, H)\\nImplies(target mutations in the PI3K/AKT pathway, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(inhibit proliferation and survival), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(H), Not(C))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(inhibit proliferation and survival))\\n--------\\nImplies(Not(H), B)\\nImplies(Not(patient is likely less sensitive to chemotherapy), target mutations in the PI3K/AKT pathway)\\n--------\\nImplies(Not(H), C)\\nImplies(Not(patient is likely less sensitive to chemotherapy), inhibit proliferation and survival)\\n--------\\nImplies(Not(H), A)\\nImplies(Not(patient is likely less sensitive to chemotherapy), using a kinase inhibitor)\\n--------\\nImplies(Not(H), Not(F))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(targets the PIK3CA mutation))\\n--------\\nImplies(Not(E), H)\\nImplies(Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(A, H)\\nImplies(using a kinase inhibitor, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(H), E)\\nImplies(Not(patient is likely less sensitive to chemotherapy), beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(Not(G), H)\\nImplies(Not(prolongs progression-free survival), patient is likely less sensitive to chemotherapy)\\n--------\\n'}",
            "3 iteration: {'syntactic validity': True, 'error code': '(* Explanation 2 provides a logical relation that treatment with alpelisib\u2013fulvestrant is beneficial for patients who had received endocrine therapy previously. *)\\n(* We can use the derived implication: Implies(D, F) *)\\n(* Since the patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant. *)\\nthen have \"Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 From e2 z \u2227 Target e2 \u2227 PIK3CAMutation z\" sledgehammer', 'solving time': 103.36587643623352, 'proof tactics': [], 'code': 'theory clinical_64_3\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  PI3KAKTPathway :: \"entity \u21d2 bool\"\\n  Using :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  AlpelisibFulvestrant :: \"entity \u21d2 bool\"\\n  PIK3CAMutation :: \"entity \u21d2 bool\"\\n  Targets :: \"event \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  Beneficial :: \"event \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  PIK3CAMutated :: \"entity \u21d2 bool\"\\n  HRPositive :: \"entity \u21d2 bool\"\\n  HER2Negative :: \"entity \u21d2 bool\"\\n  AdvancedBreastCancer :: \"entity \u21d2 bool\"\\n  For :: \"event \u21d2 entity \u21d2 bool\"\\n  EndocrineTherapy :: \"entity \u21d2 bool\"\\n  Received :: \"event \u21d2 bool\"\\n  Previously :: \"event \u21d2 bool\"\\n  Prolongs :: \"event \u21d2 bool\"\\n  ProgressionFreeSurvival :: \"event \u21d2 bool\"\\n  LessSensitive :: \"entity \u21d2 entity \u21d2 bool\"\\n  Chemotherapy :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  From :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 Mutations y \u2227 PI3KAKTPathway z \u2227 Using e1 \u2227 Patient e1 x \u2227 Target e2 \u2227 Agent e2 x \u2227 Patient e2 y \u2227 In y z \u2227 Inhibit e2 \u2227 Proliferation y \u2227 Survival y\"\\n\\n(* Explanation 2: Treatment with alpelisib\u2013fulvestrant directly targets the PIK3CA mutation and is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it prolongs progression-free survival. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2 e3. Treatment x \u2227 AlpelisibFulvestrant x \u2227 PIK3CAMutation y \u2227 Targets e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Directly e1 \u2227 Beneficial e1 \u2227 Patients z \u2227 PIK3CAMutated z \u2227 HRPositive z \u2227 HER2Negative z \u2227 AdvancedBreastCancer z \u2227 For e1 z \u2227 EndocrineTherapy w \u2227 Received e2 \u2227 Agent e2 z \u2227 Patient e2 w \u2227 Previously e2 \u2227 Prolongs e3 \u2227 ProgressionFreeSurvival e3\"\\n\\n(* Explanation 3: Patient is likely less sensitive to chemotherapy. *)\\naxiomatization where\\n  explanation_3: \"\u2200x y e. Patient e x \u2227 Chemotherapy y \u27f6 LessSensitive x y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient e x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1\"\\n  (* Hypothesis: If patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n  shows \"\u2200x y z e1 e2. (\u2203e. Patient e x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1) \u27f6 (Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 From e2 z \u2227 Target e2 \u2227 PIK3CAMutation z)\"\\nproof -\\n  (* From the premise, we have information about the patient and their previous endocrine therapy. *)\\n  from asm have \"Patient e x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1\" <ATP>\\n  (* Explanation 2 provides a logical relation that treatment with alpelisib\u2013fulvestrant is beneficial for patients who had received endocrine therapy previously. *)\\n  (* We can use the derived implication: Implies(D, F) *)\\n  (* Since the patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant. *)\\n  then have \"Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 From e2 z \u2227 Target e2 \u2227 PIK3CAMutation z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: using a kinase inhibitor (from Explanatory Sentence 1)\\nB: target mutations in the PI3K/AKT pathway (from Explanatory Sentence 1)\\nC: inhibit proliferation and survival (from Explanatory Sentence 1)\\nD: treatment with alpelisib\u2013fulvestrant (from Explanatory Sentence 2)\\nE: directly targets the PIK3CA mutation (from Explanatory Sentence 2)\\nF: beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously (from Explanatory Sentence 2)\\nG: prolongs progression-free survival (from Explanatory Sentence 2)\\nH: patient is likely less sensitive to chemotherapy (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, And(B, C))\\nImplies(using a kinase inhibitor, B & C)\\n--------\\nImplies(D, And(E, And(F, G)))\\nImplies(treatment with alpelisib\u2013fulvestrant, E & F & G)\\n--------\\nH\\npatient is likely less sensitive to chemotherapy\\n--------\\n\\nDerived Implications:\\nImplies(D, G)\\nImplies(treatment with alpelisib\u2013fulvestrant, prolongs progression-free survival)\\n--------\\nImplies(Not(H), F)\\nImplies(Not(patient is likely less sensitive to chemotherapy), beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(Not(F), Not(D))\\nImplies(Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(Not(D), H)\\nImplies(Not(treatment with alpelisib\u2013fulvestrant), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(H), D)\\nImplies(Not(patient is likely less sensitive to chemotherapy), treatment with alpelisib\u2013fulvestrant)\\n--------\\nImplies(Not(H), Not(E))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(directly targets the PIK3CA mutation))\\n--------\\nImplies(C, H)\\nImplies(inhibit proliferation and survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(H), Not(A))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(B), H)\\nImplies(Not(target mutations in the PI3K/AKT pathway), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(H), Not(B))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(target mutations in the PI3K/AKT pathway))\\n--------\\nImplies(Not(H), Not(G))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(prolongs progression-free survival))\\n--------\\nImplies(Not(E), Not(D))\\nImplies(Not(directly targets the PIK3CA mutation), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(D, F)\\nImplies(treatment with alpelisib\u2013fulvestrant, beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(D, E)\\nImplies(treatment with alpelisib\u2013fulvestrant, directly targets the PIK3CA mutation)\\n--------\\nImplies(F, H)\\nImplies(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(target mutations in the PI3K/AKT pathway), Not(using a kinase inhibitor))\\n--------\\nImplies(D, H)\\nImplies(treatment with alpelisib\u2013fulvestrant, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(A, B)\\nImplies(using a kinase inhibitor, target mutations in the PI3K/AKT pathway)\\n--------\\nImplies(Not(G), Not(D))\\nImplies(Not(prolongs progression-free survival), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(Not(F), H)\\nImplies(Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(A, C)\\nImplies(using a kinase inhibitor, inhibit proliferation and survival)\\n--------\\nImplies(Not(C), H)\\nImplies(Not(inhibit proliferation and survival), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(H), Not(D))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(E, H)\\nImplies(directly targets the PIK3CA mutation, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(A), H)\\nImplies(Not(using a kinase inhibitor), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(H), G)\\nImplies(Not(patient is likely less sensitive to chemotherapy), prolongs progression-free survival)\\n--------\\nImplies(G, H)\\nImplies(prolongs progression-free survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(B, H)\\nImplies(target mutations in the PI3K/AKT pathway, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(inhibit proliferation and survival), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(H), Not(C))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(inhibit proliferation and survival))\\n--------\\nImplies(Not(H), B)\\nImplies(Not(patient is likely less sensitive to chemotherapy), target mutations in the PI3K/AKT pathway)\\n--------\\nImplies(Not(H), C)\\nImplies(Not(patient is likely less sensitive to chemotherapy), inhibit proliferation and survival)\\n--------\\nImplies(Not(H), A)\\nImplies(Not(patient is likely less sensitive to chemotherapy), using a kinase inhibitor)\\n--------\\nImplies(Not(H), Not(F))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously))\\n--------\\nImplies(Not(E), H)\\nImplies(Not(directly targets the PIK3CA mutation), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(A, H)\\nImplies(using a kinase inhibitor, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(H), E)\\nImplies(Not(patient is likely less sensitive to chemotherapy), directly targets the PIK3CA mutation)\\n--------\\nImplies(Not(G), H)\\nImplies(Not(prolongs progression-free survival), patient is likely less sensitive to chemotherapy)\\n--------\\n'}",
            "4 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_64_4\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  PI3KAKTPathway :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n  AlpelisibFulvestrant :: \"entity\"\\n  PIK3CAMutation :: \"entity \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  PIK3CAMutated :: \"entity \u21d2 bool\"\\n  HRPositive :: \"entity \u21d2 bool\"\\n  HER2Negative :: \"entity \u21d2 bool\"\\n  AdvancedBreastCancer :: \"entity \u21d2 bool\"\\n  EndocrineTherapy :: \"entity \u21d2 bool\"\\n  Targets :: \"event \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  Beneficial :: \"event \u21d2 bool\"\\n  For :: \"event \u21d2 entity \u21d2 bool\"\\n  Received :: \"event \u21d2 bool\"\\n  Previously :: \"event \u21d2 bool\"\\n  Prolongs :: \"event \u21d2 bool\"\\n  ProgressionFreeSurvival :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  From :: \"event \u21d2 entity \u21d2 bool\"\\n  PatientEntity :: \"entity \u21d2 bool\"\\n  Chemotherapy :: \"entity \u21d2 bool\"\\n  LessSensitive :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 Mutations y \u2227 PI3KAKTPathway z \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Inhibit e2 \u2227 Agent e2 x \u2227 (\u2203p q. Patient e2 p \u2227 Proliferation p \u2227 Patient e2 q \u2227 Survival q)\"\\n\\n(* Explanation 2: Treatment with alpelisib\u2013fulvestrant directly targets the PIK3CA mutation and is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it prolongs progression-free survival. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2 e3. Treatment x \u2227 With x AlpelisibFulvestrant \u2227 PIK3CAMutation y \u2227 Patients z \u2227 PIK3CAMutated z \u2227 HRPositive z \u2227 HER2Negative z \u2227 AdvancedBreastCancer z \u2227 EndocrineTherapy w \u2227 Targets e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Directly e1 \u2227 Beneficial e2 \u2227 Agent e2 x \u2227 For e2 z \u2227 Received e3 \u2227 Agent e3 z \u2227 Patient e3 w \u2227 Previously e3 \u2227 Prolongs e3 \u2227 Agent e3 x \u2227 Prolongs e3\"\\n\\n(* Explanation 3: Patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer may benefit from treatment with alpelisib-fulvestrant. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w e1 e2. Patients x \u2227 EndocrineTherapy y \u2227 PIK3CAMutated x \u2227 HRPositive x \u2227 HER2Negative x \u2227 AdvancedBreastCancer x \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1 \u2227 Treatment z \u2227 With z AlpelisibFulvestrant \u2227 Benefit e2 \u2227 Agent e2 x \u2227 From e2 z\"\\n\\n(* Explanation 4: Patient is likely less sensitive to chemotherapy. *)\\naxiomatization where\\n  explanation_4: \"\u2200x y. PatientEntity x \u2227 Chemotherapy y \u27f6 LessSensitive x y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"PatientEntity x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1\"\\n  (* Hypothesis: If patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n  shows \"\u2200x y z e1 e2. (PatientEntity x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1) \u27f6 (Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 With z AlpelisibFulvestrant \u2227 From e2 z \u2227 (\u2203p. Target e2 p \u2227 PIK3CAMutation p))\"\\nproof -\\n  (* From the premise, we have known information about the patient entity and their previous endocrine therapy. *)\\n  from asm have \"PatientEntity x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1\" <ATP>\\n  (* Explanation 3 provides a logical relation Implies(H, I), which states that patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer may benefit from treatment with alpelisib-fulvestrant. *)\\n  (* We can use this to infer the benefit from treatment with alpelisib-fulvestrant. *)\\n  from explanation_3 have \"\u2203x y z w e1 e2. Patients x \u2227 EndocrineTherapy y \u2227 PIK3CAMutated x \u2227 HRPositive x \u2227 HER2Negative x \u2227 AdvancedBreastCancer x \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1 \u2227 Treatment z \u2227 With z AlpelisibFulvestrant \u2227 Benefit e2 \u2227 Agent e2 x \u2227 From e2 z\" <ATP>\\n  (* Since the premise matches the conditions in explanation_3, we can conclude the benefit from treatment with alpelisib-fulvestrant. *)\\n  then have \"Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 With z AlpelisibFulvestrant \u2227 From e2 z\" <ATP>\\n  (* Explanation 2 provides that treatment with alpelisib-fulvestrant directly targets the PIK3CA mutation. *)\\n  from explanation_2 have \"\u2203x y z w e1 e2 e3. Treatment x \u2227 With x AlpelisibFulvestrant \u2227 PIK3CAMutation y \u2227 Targets e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Directly e1\" <ATP>\\n  (* Therefore, we can conclude that the treatment targets the PIK3CA mutation. *)\\n  then have \"\u2203p. Target e2 p \u2227 PIK3CAMutation p\" <ATP>\\n  (* Combining these, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: using a kinase inhibitor (from Explanatory Sentence 1)\\nB: target mutations in the PI3K/AKT pathway (from Explanatory Sentence 1)\\nC: inhibit proliferation and survival (from Explanatory Sentence 1)\\nD: treatment with alpelisib\u2013fulvestrant (from Explanatory Sentence 2)\\nE: directly targets the PIK3CA mutation (from Explanatory Sentence 2)\\nF: beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously (from Explanatory Sentence 2)\\nG: prolongs progression-free survival (from Explanatory Sentence 2)\\nH: patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (from Explanatory Sentence 3)\\nI: benefit from treatment with alpelisib-fulvestrant (from Explanatory Sentence 3)\\nJ: patient is likely less sensitive to chemotherapy (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, And(B, C))\\nImplies(using a kinase inhibitor, B & C)\\n--------\\nImplies(D, And(E, And(F, G)))\\nImplies(treatment with alpelisib\u2013fulvestrant, E & F & G)\\n--------\\nImplies(H, I)\\nImplies(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, benefit from treatment with alpelisib-fulvestrant)\\n--------\\nJ\\npatient is likely less sensitive to chemotherapy\\n--------\\n\\nDerived Implications:\\nImplies(Not(J), I)\\nImplies(Not(patient is likely less sensitive to chemotherapy), benefit from treatment with alpelisib-fulvestrant)\\n--------\\nImplies(D, G)\\nImplies(treatment with alpelisib\u2013fulvestrant, prolongs progression-free survival)\\n--------\\nImplies(Not(J), Not(B))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(target mutations in the PI3K/AKT pathway))\\n--------\\nImplies(Not(F), Not(D))\\nImplies(Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(Not(H), J)\\nImplies(Not(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(I), J)\\nImplies(Not(benefit from treatment with alpelisib-fulvestrant), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(D), J)\\nImplies(Not(treatment with alpelisib\u2013fulvestrant), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(C, J)\\nImplies(inhibit proliferation and survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(B), J)\\nImplies(Not(target mutations in the PI3K/AKT pathway), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(H, J)\\nImplies(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(D))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(F, J)\\nImplies(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), G)\\nImplies(Not(patient is likely less sensitive to chemotherapy), prolongs progression-free survival)\\n--------\\nImplies(Not(E), Not(D))\\nImplies(Not(directly targets the PIK3CA mutation), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(D, F)\\nImplies(treatment with alpelisib\u2013fulvestrant, beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(D, E)\\nImplies(treatment with alpelisib\u2013fulvestrant, directly targets the PIK3CA mutation)\\n--------\\nImplies(Not(J), Not(C))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(inhibit proliferation and survival))\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(target mutations in the PI3K/AKT pathway), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(J), B)\\nImplies(Not(patient is likely less sensitive to chemotherapy), target mutations in the PI3K/AKT pathway)\\n--------\\nImplies(Not(J), Not(I))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(benefit from treatment with alpelisib-fulvestrant))\\n--------\\nImplies(D, J)\\nImplies(treatment with alpelisib\u2013fulvestrant, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), C)\\nImplies(Not(patient is likely less sensitive to chemotherapy), inhibit proliferation and survival)\\n--------\\nImplies(A, B)\\nImplies(using a kinase inhibitor, target mutations in the PI3K/AKT pathway)\\n--------\\nImplies(Not(G), Not(D))\\nImplies(Not(prolongs progression-free survival), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(Not(F), J)\\nImplies(Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), A)\\nImplies(Not(patient is likely less sensitive to chemotherapy), using a kinase inhibitor)\\n--------\\nImplies(Not(C), J)\\nImplies(Not(inhibit proliferation and survival), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(F))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously))\\n--------\\nImplies(E, J)\\nImplies(directly targets the PIK3CA mutation, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(A), J)\\nImplies(Not(using a kinase inhibitor), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(A, C)\\nImplies(using a kinase inhibitor, inhibit proliferation and survival)\\n--------\\nImplies(G, J)\\nImplies(prolongs progression-free survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), E)\\nImplies(Not(patient is likely less sensitive to chemotherapy), directly targets the PIK3CA mutation)\\n--------\\nImplies(Not(J), F)\\nImplies(Not(patient is likely less sensitive to chemotherapy), beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(B, J)\\nImplies(target mutations in the PI3K/AKT pathway, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(inhibit proliferation and survival), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(J), H)\\nImplies(Not(patient is likely less sensitive to chemotherapy), patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer)\\n--------\\nImplies(Not(E), J)\\nImplies(Not(directly targets the PIK3CA mutation), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(H))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer))\\n--------\\nImplies(Not(J), D)\\nImplies(Not(patient is likely less sensitive to chemotherapy), treatment with alpelisib\u2013fulvestrant)\\n--------\\nImplies(A, J)\\nImplies(using a kinase inhibitor, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(E))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(directly targets the PIK3CA mutation))\\n--------\\nImplies(I, J)\\nImplies(benefit from treatment with alpelisib-fulvestrant, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(G), J)\\nImplies(Not(prolongs progression-free survival), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(A))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(J), Not(G))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(prolongs progression-free survival))\\n--------\\n'}",
            "5 iteration: {'syntactic validity': True, 'error code': '(* Explanation 3 provides a logical relation Implies(H, I), which states that patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer benefit from treatment with alpelisib-fulvestrant. *)\\n(* We can use this to infer that the patient may benefit from the treatment. *)\\nthen have \"Benefit e2 \u2227 Agent e2 x \u2227 From e2 z \u2227 Treatment z \u2227 AlpelisibFulvestrant z\" sledgehammer', 'solving time': 103.38584995269775, 'proof tactics': [], 'code': 'theory clinical_64_5\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  PI3KAKTPathway :: \"entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  AlpelisibFulvestrant :: \"entity \u21d2 bool\"\\n  PIK3CAMutation :: \"entity \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  PIK3CAMutated :: \"entity \u21d2 bool\"\\n  HRPositive :: \"entity \u21d2 bool\"\\n  HER2Negative :: \"entity \u21d2 bool\"\\n  AdvancedBreastCancer :: \"entity \u21d2 bool\"\\n  EndocrineTherapy :: \"entity \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  Beneficial :: \"event \u21d2 bool\"\\n  For :: \"event \u21d2 entity \u21d2 bool\"\\n  Received :: \"event \u21d2 bool\"\\n  Previously :: \"event \u21d2 bool\"\\n  Prolongs :: \"event \u21d2 bool\"\\n  ProgressionFreeSurvival :: \"event \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  From :: \"event \u21d2 entity \u21d2 bool\"\\n  PatientEntity :: \"entity \u21d2 bool\"\\n  Chemotherapy :: \"entity \u21d2 bool\"\\n  LikelyLessSensitiveTo :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 Mutations y \u2227 PI3KAKTPathway y \u2227 Proliferation z \u2227 Survival z \u2227 (Target e1 \u2227 Agent e1 x \u2227 Patient e1 y) \u2227 (Inhibit e2 \u2227 Agent e2 x \u2227 Patient e2 z)\"\\n\\n(* Explanation 2: Treatment with alpelisib\u2013fulvestrant directly targets the PIK3CA mutation and is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it prolongs progression-free survival. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2 e3. Treatment x \u2227 AlpelisibFulvestrant x \u2227 PIK3CAMutation y \u2227 Patients z \u2227 PIK3CAMutated z \u2227 HRPositive z \u2227 HER2Negative z \u2227 AdvancedBreastCancer z \u2227 EndocrineTherapy w \u2227 (Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Directly e1) \u2227 (Beneficial e2 \u2227 For e2 z \u2227 Received e3 \u2227 Agent e3 z \u2227 Patient e3 w \u2227 Previously e3) \u2227 (Prolongs e2 \u2227 Agent e2 x \u2227 ProgressionFreeSurvival e2)\"\\n\\n(* Explanation 3: Patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer may benefit from treatment with alpelisib-fulvestrant. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w e1 e2. Patients x \u2227 EndocrineTherapy y \u2227 PIK3CAMutated x \u2227 HRPositive x \u2227 HER2Negative x \u2227 AdvancedBreastCancer x \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 (Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1) \u2227 (Benefit e2 \u2227 Agent e2 x \u2227 From e2 z)\"\\n\\n(* Explanation 4: Patient is likely less sensitive to chemotherapy. *)\\naxiomatization where\\n  explanation_4: \"\u2200x y. PatientEntity x \u2227 Chemotherapy y \u27f6 LikelyLessSensitiveTo x y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"PatientEntity x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1\"\\n  (* Hypothesis: If patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation *)\\n  shows \"\u2200x y z e1 e2. (PatientEntity x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1) \u27f6 (Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 From e2 z \u2227 AlpelisibFulvestrant z \u2227 (\u2203v. Target e2 \u2227 PIK3CAMutation v))\"\\nproof -\\n  (* From the premise, we have information about the patient entity and their previous endocrine therapy. *)\\n  from asm have \"PatientEntity x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1\" <ATP>\\n  (* Explanation 3 provides a logical relation Implies(H, I), which states that patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer benefit from treatment with alpelisib-fulvestrant. *)\\n  (* We can use this to infer that the patient may benefit from the treatment. *)\\n  then have \"Benefit e2 \u2227 Agent e2 x \u2227 From e2 z \u2227 Treatment z \u2227 AlpelisibFulvestrant z\" <ATP>\\n  (* Explanation 2 states that treatment with alpelisib\u2013fulvestrant directly targets the PIK3CA mutation. *)\\n  (* Therefore, we can conclude that there exists a PIK3CA mutation targeted by the treatment. *)\\n  then have \"\u2203v. Target e2 \u2227 PIK3CAMutation v\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: using a kinase inhibitor (from Explanatory Sentence 1)\\nB: target mutations in the PI3K/AKT pathway (from Explanatory Sentence 1)\\nC: inhibit proliferation and survival (from Explanatory Sentence 1)\\nD: treatment with alpelisib\u2013fulvestrant (from Explanatory Sentence 2)\\nE: directly targets the PIK3CA mutation (from Explanatory Sentence 2)\\nF: beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously (from Explanatory Sentence 2)\\nG: prolongs progression-free survival (from Explanatory Sentence 2)\\nH: patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (from Explanatory Sentence 3)\\nI: benefit from treatment with alpelisib-fulvestrant (from Explanatory Sentence 3)\\nJ: patient is likely less sensitive to chemotherapy (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, And(B, C))\\nImplies(using a kinase inhibitor, B & C)\\n--------\\nImplies(D, And(E, And(F, G)))\\nImplies(treatment with alpelisib\u2013fulvestrant, E & F & G)\\n--------\\nImplies(H, I)\\nImplies(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, benefit from treatment with alpelisib-fulvestrant)\\n--------\\nJ\\npatient is likely less sensitive to chemotherapy\\n--------\\n\\nDerived Implications:\\nImplies(Not(J), I)\\nImplies(Not(patient is likely less sensitive to chemotherapy), benefit from treatment with alpelisib-fulvestrant)\\n--------\\nImplies(D, G)\\nImplies(treatment with alpelisib\u2013fulvestrant, prolongs progression-free survival)\\n--------\\nImplies(Not(J), Not(B))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(target mutations in the PI3K/AKT pathway))\\n--------\\nImplies(Not(F), Not(D))\\nImplies(Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(Not(H), J)\\nImplies(Not(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(I), J)\\nImplies(Not(benefit from treatment with alpelisib-fulvestrant), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(D), J)\\nImplies(Not(treatment with alpelisib\u2013fulvestrant), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(C, J)\\nImplies(inhibit proliferation and survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(B), J)\\nImplies(Not(target mutations in the PI3K/AKT pathway), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(H, J)\\nImplies(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(D))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(F, J)\\nImplies(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), G)\\nImplies(Not(patient is likely less sensitive to chemotherapy), prolongs progression-free survival)\\n--------\\nImplies(Not(E), Not(D))\\nImplies(Not(directly targets the PIK3CA mutation), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(D, F)\\nImplies(treatment with alpelisib\u2013fulvestrant, beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(D, E)\\nImplies(treatment with alpelisib\u2013fulvestrant, directly targets the PIK3CA mutation)\\n--------\\nImplies(Not(J), Not(C))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(inhibit proliferation and survival))\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(target mutations in the PI3K/AKT pathway), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(J), B)\\nImplies(Not(patient is likely less sensitive to chemotherapy), target mutations in the PI3K/AKT pathway)\\n--------\\nImplies(Not(J), Not(I))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(benefit from treatment with alpelisib-fulvestrant))\\n--------\\nImplies(D, J)\\nImplies(treatment with alpelisib\u2013fulvestrant, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), C)\\nImplies(Not(patient is likely less sensitive to chemotherapy), inhibit proliferation and survival)\\n--------\\nImplies(A, B)\\nImplies(using a kinase inhibitor, target mutations in the PI3K/AKT pathway)\\n--------\\nImplies(Not(G), Not(D))\\nImplies(Not(prolongs progression-free survival), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(Not(F), J)\\nImplies(Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), A)\\nImplies(Not(patient is likely less sensitive to chemotherapy), using a kinase inhibitor)\\n--------\\nImplies(Not(C), J)\\nImplies(Not(inhibit proliferation and survival), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(F))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously))\\n--------\\nImplies(E, J)\\nImplies(directly targets the PIK3CA mutation, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(A), J)\\nImplies(Not(using a kinase inhibitor), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(A, C)\\nImplies(using a kinase inhibitor, inhibit proliferation and survival)\\n--------\\nImplies(G, J)\\nImplies(prolongs progression-free survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), E)\\nImplies(Not(patient is likely less sensitive to chemotherapy), directly targets the PIK3CA mutation)\\n--------\\nImplies(Not(J), F)\\nImplies(Not(patient is likely less sensitive to chemotherapy), beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(B, J)\\nImplies(target mutations in the PI3K/AKT pathway, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(inhibit proliferation and survival), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(J), H)\\nImplies(Not(patient is likely less sensitive to chemotherapy), patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer)\\n--------\\nImplies(Not(E), J)\\nImplies(Not(directly targets the PIK3CA mutation), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(H))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer))\\n--------\\nImplies(Not(J), D)\\nImplies(Not(patient is likely less sensitive to chemotherapy), treatment with alpelisib\u2013fulvestrant)\\n--------\\nImplies(A, J)\\nImplies(using a kinase inhibitor, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(E))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(directly targets the PIK3CA mutation))\\n--------\\nImplies(I, J)\\nImplies(benefit from treatment with alpelisib-fulvestrant, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(G), J)\\nImplies(Not(prolongs progression-free survival), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(A))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(J), Not(G))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(prolongs progression-free survival))\\n--------\\n'}",
            "6 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 8.942950010299683, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"bool\"\\n\\nType error in application: operator not of function type\\n\\nOperator:  Target e2 :: bool\\nOperand:   z :: entity\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_64_6\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  PI3KAKTPathway :: \"entity \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  AlpelisibFulvestrant :: \"entity \u21d2 bool\"\\n  PIK3CAMutation :: \"entity \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  PIK3CAMutated :: \"entity \u21d2 bool\"\\n  HRPositive :: \"entity \u21d2 bool\"\\n  HER2Negative :: \"entity \u21d2 bool\"\\n  AdvancedBreastCancer :: \"entity \u21d2 bool\"\\n  EndocrineTherapy :: \"entity \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  Beneficial :: \"event \u21d2 bool\"\\n  For :: \"event \u21d2 entity \u21d2 bool\"\\n  Received :: \"event \u21d2 bool\"\\n  Previously :: \"event \u21d2 bool\"\\n  Prolongs :: \"event \u21d2 bool\"\\n  ProgressionFreeSurvival :: \"event \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  From :: \"event \u21d2 entity \u21d2 bool\"\\n  Chemotherapy :: \"entity \u21d2 bool\"\\n  LikelyLessSensitiveTo :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 Mutations y \u2227 PI3KAKTPathway y \u2227 Proliferation z \u2227 Survival z \u2227 (Target e1 \u2227 Agent e1 x \u2227 Patient e1 y) \u2227 (Inhibit e2 \u2227 Agent e2 x \u2227 Patient e2 z)\"\\n\\n(* Explanation 2: Treatment with alpelisib\u2013fulvestrant directly targets the PIK3CA mutation and is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it prolongs progression-free survival. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2 e3. Treatment x \u2227 AlpelisibFulvestrant x \u2227 PIK3CAMutation y \u2227 Patients z \u2227 PIK3CAMutated z \u2227 HRPositive z \u2227 HER2Negative z \u2227 AdvancedBreastCancer z \u2227 EndocrineTherapy w \u2227 (Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Directly e1) \u2227 (Beneficial e2 \u2227 For e2 z) \u2227 (Received e3 \u2227 Agent e3 z \u2227 Patient e3 w \u2227 Previously e3) \u2227 (Prolongs e2 \u2227 Agent e2 x \u2227 ProgressionFreeSurvival e2)\"\\n\\n(* Explanation 3: Patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer may benefit from treatment with alpelisib-fulvestrant, which targets the PIK3CA mutation. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w e1 e2 e3. Patients x \u2227 EndocrineTherapy y \u2227 PIK3CAMutated x \u2227 HRPositive x \u2227 HER2Negative x \u2227 AdvancedBreastCancer x \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 PIK3CAMutation w \u2227 (Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1) \u2227 (Benefit e2 \u2227 Agent e2 x \u2227 From e2 z) \u2227 (Target e3 \u2227 Agent e3 z \u2227 Patient e3 w)\"\\n\\n(* Explanation 4: Patient is likely less sensitive to chemotherapy. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y. Patients x \u2227 Chemotherapy y \u2227 LikelyLessSensitiveTo x y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1\"\\n  (* Hypothesis: If patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n  shows \"\u2200x y z e1 e2. (\u2203e1. Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1) \u27f6 (Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 From e2 z \u2227 AlpelisibFulvestrant z \u2227 Target e2 z \u2227 PIK3CAMutation z)\"\\nproof -\\n  (* From the premise, we know that the patient has previously received endocrine therapy. *)\\n  from asm have \"Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1\" <ATP>\\n  (* Explanation 3 states that patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer may benefit from treatment with alpelisib-fulvestrant, which targets the PIK3CA mutation. *)\\n  (* We can use this explanation to infer the benefit of treatment with alpelisib-fulvestrant. *)\\n  then have \"Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 From e2 z \u2227 AlpelisibFulvestrant z \u2227 Target e2 z \u2227 PIK3CAMutation z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: using a kinase inhibitor (from Explanatory Sentence 1)\\nB: target mutations in the PI3K/AKT pathway (from Explanatory Sentence 1)\\nC: inhibit proliferation and survival (from Explanatory Sentence 1)\\nD: treatment with alpelisib\u2013fulvestrant (from Explanatory Sentence 2)\\nE: directly targets the PIK3CA mutation (from Explanatory Sentence 2)\\nF: beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously (from Explanatory Sentence 2)\\nG: prolongs progression-free survival (from Explanatory Sentence 2)\\nH: patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (from Explanatory Sentence 3)\\nI: benefit from treatment with alpelisib-fulvestrant (from Explanatory Sentence 3)\\nJ: patient is likely less sensitive to chemotherapy (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, And(B, C))\\nImplies(using a kinase inhibitor, B & C)\\n--------\\nImplies(D, And(E, And(F, G)))\\nImplies(treatment with alpelisib\u2013fulvestrant, E & F & G)\\n--------\\nImplies(H, I)\\nImplies(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, benefit from treatment with alpelisib-fulvestrant)\\n--------\\nJ\\npatient is likely less sensitive to chemotherapy\\n--------\\n\\nDerived Implications:\\nImplies(Not(J), I)\\nImplies(Not(patient is likely less sensitive to chemotherapy), benefit from treatment with alpelisib-fulvestrant)\\n--------\\nImplies(D, G)\\nImplies(treatment with alpelisib\u2013fulvestrant, prolongs progression-free survival)\\n--------\\nImplies(Not(J), Not(B))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(target mutations in the PI3K/AKT pathway))\\n--------\\nImplies(Not(F), Not(D))\\nImplies(Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(Not(H), J)\\nImplies(Not(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(I), J)\\nImplies(Not(benefit from treatment with alpelisib-fulvestrant), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(D), J)\\nImplies(Not(treatment with alpelisib\u2013fulvestrant), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(C, J)\\nImplies(inhibit proliferation and survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(B), J)\\nImplies(Not(target mutations in the PI3K/AKT pathway), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(H, J)\\nImplies(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(D))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(F, J)\\nImplies(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), G)\\nImplies(Not(patient is likely less sensitive to chemotherapy), prolongs progression-free survival)\\n--------\\nImplies(Not(E), Not(D))\\nImplies(Not(directly targets the PIK3CA mutation), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(D, F)\\nImplies(treatment with alpelisib\u2013fulvestrant, beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(D, E)\\nImplies(treatment with alpelisib\u2013fulvestrant, directly targets the PIK3CA mutation)\\n--------\\nImplies(Not(J), Not(C))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(inhibit proliferation and survival))\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(target mutations in the PI3K/AKT pathway), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(J), B)\\nImplies(Not(patient is likely less sensitive to chemotherapy), target mutations in the PI3K/AKT pathway)\\n--------\\nImplies(Not(J), Not(I))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(benefit from treatment with alpelisib-fulvestrant))\\n--------\\nImplies(D, J)\\nImplies(treatment with alpelisib\u2013fulvestrant, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), C)\\nImplies(Not(patient is likely less sensitive to chemotherapy), inhibit proliferation and survival)\\n--------\\nImplies(A, B)\\nImplies(using a kinase inhibitor, target mutations in the PI3K/AKT pathway)\\n--------\\nImplies(Not(G), Not(D))\\nImplies(Not(prolongs progression-free survival), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(Not(F), J)\\nImplies(Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), A)\\nImplies(Not(patient is likely less sensitive to chemotherapy), using a kinase inhibitor)\\n--------\\nImplies(Not(C), J)\\nImplies(Not(inhibit proliferation and survival), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(F))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously))\\n--------\\nImplies(E, J)\\nImplies(directly targets the PIK3CA mutation, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(A), J)\\nImplies(Not(using a kinase inhibitor), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(A, C)\\nImplies(using a kinase inhibitor, inhibit proliferation and survival)\\n--------\\nImplies(G, J)\\nImplies(prolongs progression-free survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), E)\\nImplies(Not(patient is likely less sensitive to chemotherapy), directly targets the PIK3CA mutation)\\n--------\\nImplies(Not(J), F)\\nImplies(Not(patient is likely less sensitive to chemotherapy), beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(B, J)\\nImplies(target mutations in the PI3K/AKT pathway, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(inhibit proliferation and survival), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(J), H)\\nImplies(Not(patient is likely less sensitive to chemotherapy), patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer)\\n--------\\nImplies(Not(E), J)\\nImplies(Not(directly targets the PIK3CA mutation), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(H))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer))\\n--------\\nImplies(Not(J), D)\\nImplies(Not(patient is likely less sensitive to chemotherapy), treatment with alpelisib\u2013fulvestrant)\\n--------\\nImplies(A, J)\\nImplies(using a kinase inhibitor, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(E))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(directly targets the PIK3CA mutation))\\n--------\\nImplies(I, J)\\nImplies(benefit from treatment with alpelisib-fulvestrant, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(G), J)\\nImplies(Not(prolongs progression-free survival), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(A))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(J), Not(G))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(prolongs progression-free survival))\\n--------\\n'}",
            "7 iteration: {'syntactic validity': True, 'error code': '(* Explanation 3 provides that such patients may benefit from treatment with alpelisib-fulvestrant. *)\\n(* There is a logical relation Implies(H, I), which states that patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer benefit from treatment with alpelisib-fulvestrant. *)\\nthen have \"Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 From e2 z \u2227 AlpelisibFulvestrant z \u2227 Target e2 \u2227 PIK3CAMutation z\" sledgehammer', 'solving time': 103.35768055915833, 'proof tactics': [], 'code': 'theory clinical_64_7\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  PI3KAKTPathway :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Proliferation :: \"event \u21d2 bool\"\\n  Survival :: \"event \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  AlpelisibFulvestrant :: \"entity \u21d2 bool\"\\n  PIK3CAMutation :: \"entity \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  PIK3CAMutated :: \"entity \u21d2 bool\"\\n  HRPositive :: \"entity \u21d2 bool\"\\n  HER2Negative :: \"entity \u21d2 bool\"\\n  AdvancedBreastCancer :: \"entity \u21d2 bool\"\\n  EndocrineTherapy :: \"entity \u21d2 bool\"\\n  Received :: \"event \u21d2 bool\"\\n  Previously :: \"event \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  Beneficial :: \"event \u21d2 entity \u21d2 bool\"\\n  Prolongs :: \"event \u21d2 bool\"\\n  ProgressionFreeSurvival :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  From :: \"event \u21d2 entity \u21d2 bool\"\\n  Chemotherapy :: \"entity \u21d2 bool\"\\n  LessSensitive :: \"entity \u21d2 entity \u21d2 bool\"\\n  PatientEntity :: \"entity \u21d2 bool\"  (* Corrected to entity type *)\\n\\n(* Explanation 1: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 Mutations y \u2227 PI3KAKTPathway z \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Inhibit e2 \u2227 Proliferation e2 \u2227 Survival e2\"\\n\\n(* Explanation 2: Treatment with alpelisib\u2013fulvestrant directly targets the PIK3CA mutation and is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it prolongs progression-free survival. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w v e1 e2 e3. Treatment x \u2227 AlpelisibFulvestrant x \u2227 PIK3CAMutation y \u2227 Patients z \u2227 PIK3CAMutated z \u2227 HRPositive z \u2227 HER2Negative z \u2227 AdvancedBreastCancer z \u2227 EndocrineTherapy w \u2227 Received e1 \u2227 Agent e1 z \u2227 Patient e1 w \u2227 Previously e1 \u2227 Target e2 \u2227 Agent e2 x \u2227 Patient e2 y \u2227 Directly e2 \u2227 Beneficial e2 z \u2227 Prolongs e3 \u2227 ProgressionFreeSurvival v \u2227 Patient e3 v\"\\n\\n(* Explanation 3: Patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer may benefit from treatment with alpelisib-fulvestrant, which targets the PIK3CA mutation. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w v e1 e2 e3. Patients x \u2227 EndocrineTherapy y \u2227 PIK3CAMutated x \u2227 HRPositive x \u2227 HER2Negative x \u2227 AdvancedBreastCancer x \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1 \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 Benefit e2 \u2227 Agent e2 x \u2227 From e2 z \u2227 PIK3CAMutation w \u2227 Target e3 \u2227 Agent e3 z \u2227 Patient e3 w\"\\n\\n(* Explanation 4: Patient is likely less sensitive to chemotherapy. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y. PatientEntity x \u2227 Chemotherapy y \u2227 LessSensitive x y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"PatientEntity x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1\"\\n  (* Hypothesis: If patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n  shows \"\u2200x y z e1 e2. (PatientEntity x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1) \u27f6 (Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 From e2 z \u2227 AlpelisibFulvestrant z \u2227 Target e2 \u2227 PIK3CAMutation z)\"\\nproof -\\n  (* From the premise, we have information about the patient receiving endocrine therapy previously. *)\\n  from asm have \"PatientEntity x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1\" <ATP>\\n  (* Explanation 3 provides that such patients may benefit from treatment with alpelisib-fulvestrant. *)\\n  (* There is a logical relation Implies(H, I), which states that patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer benefit from treatment with alpelisib-fulvestrant. *)\\n  then have \"Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 From e2 z \u2227 AlpelisibFulvestrant z \u2227 Target e2 \u2227 PIK3CAMutation z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: using a kinase inhibitor (from Explanatory Sentence 1)\\nB: target mutations in the PI3K/AKT pathway (from Explanatory Sentence 1)\\nC: inhibit proliferation and survival (from Explanatory Sentence 1)\\nD: treatment with alpelisib\u2013fulvestrant (from Explanatory Sentence 2)\\nE: directly targets the PIK3CA mutation (from Explanatory Sentence 2)\\nF: beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously (from Explanatory Sentence 2)\\nG: prolongs progression-free survival (from Explanatory Sentence 2)\\nH: patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (from Explanatory Sentence 3)\\nI: benefit from treatment with alpelisib-fulvestrant (from Explanatory Sentence 3)\\nJ: patient is likely less sensitive to chemotherapy (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, And(B, C))\\nImplies(using a kinase inhibitor, B & C)\\n--------\\nImplies(D, And(E, And(F, G)))\\nImplies(treatment with alpelisib\u2013fulvestrant, E & F & G)\\n--------\\nImplies(H, I)\\nImplies(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, benefit from treatment with alpelisib-fulvestrant)\\n--------\\nJ\\npatient is likely less sensitive to chemotherapy\\n--------\\n\\nDerived Implications:\\nImplies(Not(J), I)\\nImplies(Not(patient is likely less sensitive to chemotherapy), benefit from treatment with alpelisib-fulvestrant)\\n--------\\nImplies(D, G)\\nImplies(treatment with alpelisib\u2013fulvestrant, prolongs progression-free survival)\\n--------\\nImplies(Not(J), Not(B))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(target mutations in the PI3K/AKT pathway))\\n--------\\nImplies(Not(F), Not(D))\\nImplies(Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(Not(H), J)\\nImplies(Not(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(I), J)\\nImplies(Not(benefit from treatment with alpelisib-fulvestrant), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(D), J)\\nImplies(Not(treatment with alpelisib\u2013fulvestrant), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(C, J)\\nImplies(inhibit proliferation and survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(B), J)\\nImplies(Not(target mutations in the PI3K/AKT pathway), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(H, J)\\nImplies(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(D))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(F, J)\\nImplies(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), G)\\nImplies(Not(patient is likely less sensitive to chemotherapy), prolongs progression-free survival)\\n--------\\nImplies(Not(E), Not(D))\\nImplies(Not(directly targets the PIK3CA mutation), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(D, F)\\nImplies(treatment with alpelisib\u2013fulvestrant, beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(D, E)\\nImplies(treatment with alpelisib\u2013fulvestrant, directly targets the PIK3CA mutation)\\n--------\\nImplies(Not(J), Not(C))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(inhibit proliferation and survival))\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(target mutations in the PI3K/AKT pathway), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(J), B)\\nImplies(Not(patient is likely less sensitive to chemotherapy), target mutations in the PI3K/AKT pathway)\\n--------\\nImplies(Not(J), Not(I))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(benefit from treatment with alpelisib-fulvestrant))\\n--------\\nImplies(D, J)\\nImplies(treatment with alpelisib\u2013fulvestrant, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), C)\\nImplies(Not(patient is likely less sensitive to chemotherapy), inhibit proliferation and survival)\\n--------\\nImplies(A, B)\\nImplies(using a kinase inhibitor, target mutations in the PI3K/AKT pathway)\\n--------\\nImplies(Not(G), Not(D))\\nImplies(Not(prolongs progression-free survival), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(Not(F), J)\\nImplies(Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), A)\\nImplies(Not(patient is likely less sensitive to chemotherapy), using a kinase inhibitor)\\n--------\\nImplies(Not(C), J)\\nImplies(Not(inhibit proliferation and survival), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(F))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously))\\n--------\\nImplies(E, J)\\nImplies(directly targets the PIK3CA mutation, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(A), J)\\nImplies(Not(using a kinase inhibitor), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(A, C)\\nImplies(using a kinase inhibitor, inhibit proliferation and survival)\\n--------\\nImplies(G, J)\\nImplies(prolongs progression-free survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), E)\\nImplies(Not(patient is likely less sensitive to chemotherapy), directly targets the PIK3CA mutation)\\n--------\\nImplies(Not(J), F)\\nImplies(Not(patient is likely less sensitive to chemotherapy), beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(B, J)\\nImplies(target mutations in the PI3K/AKT pathway, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(inhibit proliferation and survival), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(J), H)\\nImplies(Not(patient is likely less sensitive to chemotherapy), patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer)\\n--------\\nImplies(Not(E), J)\\nImplies(Not(directly targets the PIK3CA mutation), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(H))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer))\\n--------\\nImplies(Not(J), D)\\nImplies(Not(patient is likely less sensitive to chemotherapy), treatment with alpelisib\u2013fulvestrant)\\n--------\\nImplies(A, J)\\nImplies(using a kinase inhibitor, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(E))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(directly targets the PIK3CA mutation))\\n--------\\nImplies(I, J)\\nImplies(benefit from treatment with alpelisib-fulvestrant, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(G), J)\\nImplies(Not(prolongs progression-free survival), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(A))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(J), Not(G))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(prolongs progression-free survival))\\n--------\\n'}",
            "8 iteration: {'syntactic validity': True, 'error code': '(* Explanation 3 states that patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer benefit from treatment with alpelisib-fulvestrant. *)\\n(* This aligns with the logical relation Implies(H, I), where H is the condition of having previously received endocrine therapy and having PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, and I is the benefit from treatment with alpelisib-fulvestrant. *)\\n(* Since the premise matches the condition H, we can infer the benefit I. *)\\nthen have \"Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 From e2 z \u2227 Target e2 \u2227 PIK3CAMutation z\" sledgehammer', 'solving time': 103.21244859695435, 'proof tactics': [], 'code': 'theory clinical_64_8\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  PI3KAKTPathway :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  AlpelisibFulvestrant :: \"entity \u21d2 bool\"\\n  PIK3CAMutation :: \"entity \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  Beneficial :: \"event \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  PIK3CAMutated :: \"entity \u21d2 bool\"\\n  HRPositive :: \"entity \u21d2 bool\"\\n  HER2Negative :: \"entity \u21d2 bool\"\\n  AdvancedBreastCancer :: \"entity \u21d2 bool\"\\n  EndocrineTherapy :: \"entity \u21d2 bool\"\\n  Received :: \"event \u21d2 bool\"\\n  Previously :: \"event \u21d2 bool\"\\n  Prolongs :: \"event \u21d2 bool\"\\n  ProgressionFreeSurvival :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  From :: \"event \u21d2 entity \u21d2 bool\"\\n  Improve :: \"event \u21d2 bool\"\\n  Outcomes :: \"entity \u21d2 bool\"\\n  PatientEntity :: \"entity \u21d2 bool\"\\n  Chemotherapy :: \"entity \u21d2 bool\"\\n  LessSensitive :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 Mutations y \u2227 PI3KAKTPathway z \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Inhibit e2 \u2227 Agent e2 x \u2227 Proliferation y \u2227 Survival y\"\\n\\n(* Explanation 2: Treatment with alpelisib\u2013fulvestrant directly targets the PIK3CA mutation and is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it prolongs progression-free survival. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2 e3. Treatment x \u2227 AlpelisibFulvestrant x \u2227 PIK3CAMutation y \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Directly e1 \u2227 Beneficial e2 \u2227 Patients z \u2227 PIK3CAMutated z \u2227 HRPositive z \u2227 HER2Negative z \u2227 AdvancedBreastCancer z \u2227 EndocrineTherapy w \u2227 Received e3 \u2227 Agent e3 z \u2227 Patient e3 w \u2227 Previously e3 \u2227 Prolongs e2 \u2227 ProgressionFreeSurvival y\"\\n\\n(* Explanation 3: Patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer benefit from treatment with alpelisib-fulvestrant, which targets the PIK3CA mutation and improves outcomes. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w e1 e2 e3 e4. Patients x \u2227 EndocrineTherapy y \u2227 PIK3CAMutated x \u2227 HRPositive x \u2227 HER2Negative x \u2227 AdvancedBreastCancer x \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1 \u2227 Benefit e2 \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 From e2 z \u2227 PIK3CAMutation w \u2227 Target e3 \u2227 Agent e3 z \u2227 Patient e3 w \u2227 Improve e4 \u2227 Agent e4 z \u2227 Outcomes w\"\\n\\n(* Explanation 4: Patient is likely less sensitive to chemotherapy. *)\\naxiomatization where\\n  explanation_4: \"\u2200x y. PatientEntity x \u2227 Chemotherapy y \u27f6 LessSensitive x y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"PatientEntity x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1\"\\n  (* Hypothesis: If patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n  shows \"(\u2200x y z e1 e2. PatientEntity x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1 \u27f6 (Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 From e2 z \u2227 Target e2 \u2227 PIK3CAMutation z))\"\\nproof -\\n  (* From the premise, we have information about the patient entity and their previous endocrine therapy. *)\\n  from asm have \"PatientEntity x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1\" <ATP>\\n  (* Explanation 3 states that patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer benefit from treatment with alpelisib-fulvestrant. *)\\n  (* This aligns with the logical relation Implies(H, I), where H is the condition of having previously received endocrine therapy and having PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, and I is the benefit from treatment with alpelisib-fulvestrant. *)\\n  (* Since the premise matches the condition H, we can infer the benefit I. *)\\n  then have \"Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 From e2 z \u2227 Target e2 \u2227 PIK3CAMutation z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: using a kinase inhibitor (from Explanatory Sentence 1)\\nB: target mutations in the PI3K/AKT pathway (from Explanatory Sentence 1)\\nC: inhibit proliferation and survival (from Explanatory Sentence 1)\\nD: treatment with alpelisib\u2013fulvestrant (from Explanatory Sentence 2)\\nE: directly targets the PIK3CA mutation (from Explanatory Sentence 2)\\nF: beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously (from Explanatory Sentence 2)\\nG: prolongs progression-free survival (from Explanatory Sentence 2)\\nH: patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (from Explanatory Sentence 3)\\nI: benefit from treatment with alpelisib-fulvestrant (from Explanatory Sentence 3)\\nJ: improves outcomes (from Explanatory Sentence 3)\\nK: patient is likely less sensitive to chemotherapy (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, And(B, C))\\nImplies(using a kinase inhibitor, B & C)\\n--------\\nImplies(D, And(E, And(F, G)))\\nImplies(treatment with alpelisib\u2013fulvestrant, E & F & G)\\n--------\\nImplies(H, And(I, J))\\nImplies(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, I & J)\\n--------\\nK\\npatient is likely less sensitive to chemotherapy\\n--------\\n\\nDerived Implications:\\nImplies(D, G)\\nImplies(treatment with alpelisib\u2013fulvestrant, prolongs progression-free survival)\\n--------\\nImplies(Not(K), D)\\nImplies(Not(patient is likely less sensitive to chemotherapy), treatment with alpelisib\u2013fulvestrant)\\n--------\\nImplies(Not(K), Not(E))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(directly targets the PIK3CA mutation))\\n--------\\nImplies(Not(F), Not(D))\\nImplies(Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(C, K)\\nImplies(inhibit proliferation and survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(K), Not(J))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(improves outcomes))\\n--------\\nImplies(Not(I), Not(H))\\nImplies(Not(benefit from treatment with alpelisib-fulvestrant), Not(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer))\\n--------\\nImplies(Not(K), Not(A))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(using a kinase inhibitor))\\n--------\\nImplies(H, K)\\nImplies(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(B), K)\\nImplies(Not(target mutations in the PI3K/AKT pathway), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(K), Not(G))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(prolongs progression-free survival))\\n--------\\nImplies(Not(K), I)\\nImplies(Not(patient is likely less sensitive to chemotherapy), benefit from treatment with alpelisib-fulvestrant)\\n--------\\nImplies(Not(K), Not(B))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(target mutations in the PI3K/AKT pathway))\\n--------\\nImplies(F, K)\\nImplies(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(H, J)\\nImplies(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, improves outcomes)\\n--------\\nImplies(D, K)\\nImplies(treatment with alpelisib\u2013fulvestrant, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(E), Not(D))\\nImplies(Not(directly targets the PIK3CA mutation), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(D, F)\\nImplies(treatment with alpelisib\u2013fulvestrant, beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(Not(F), K)\\nImplies(Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(D, E)\\nImplies(treatment with alpelisib\u2013fulvestrant, directly targets the PIK3CA mutation)\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(target mutations in the PI3K/AKT pathway), Not(using a kinase inhibitor))\\n--------\\nImplies(J, K)\\nImplies(improves outcomes, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(C), K)\\nImplies(Not(inhibit proliferation and survival), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(E, K)\\nImplies(directly targets the PIK3CA mutation, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(A), K)\\nImplies(Not(using a kinase inhibitor), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(K), Not(D))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(G, K)\\nImplies(prolongs progression-free survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(A, B)\\nImplies(using a kinase inhibitor, target mutations in the PI3K/AKT pathway)\\n--------\\nImplies(Not(K), G)\\nImplies(Not(patient is likely less sensitive to chemotherapy), prolongs progression-free survival)\\n--------\\nImplies(Not(G), Not(D))\\nImplies(Not(prolongs progression-free survival), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(H, I)\\nImplies(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, benefit from treatment with alpelisib-fulvestrant)\\n--------\\nImplies(B, K)\\nImplies(target mutations in the PI3K/AKT pathway, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(K), Not(C))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(inhibit proliferation and survival))\\n--------\\nImplies(A, C)\\nImplies(using a kinase inhibitor, inhibit proliferation and survival)\\n--------\\nImplies(Not(K), B)\\nImplies(Not(patient is likely less sensitive to chemotherapy), target mutations in the PI3K/AKT pathway)\\n--------\\nImplies(Not(K), Not(I))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(benefit from treatment with alpelisib-fulvestrant))\\n--------\\nImplies(Not(K), C)\\nImplies(Not(patient is likely less sensitive to chemotherapy), inhibit proliferation and survival)\\n--------\\nImplies(Not(J), K)\\nImplies(Not(improves outcomes), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(K), A)\\nImplies(Not(patient is likely less sensitive to chemotherapy), using a kinase inhibitor)\\n--------\\nImplies(A, K)\\nImplies(using a kinase inhibitor, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(K), Not(F))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously))\\n--------\\nImplies(Not(E), K)\\nImplies(Not(directly targets the PIK3CA mutation), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(inhibit proliferation and survival), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(K), E)\\nImplies(Not(patient is likely less sensitive to chemotherapy), directly targets the PIK3CA mutation)\\n--------\\nImplies(I, K)\\nImplies(benefit from treatment with alpelisib-fulvestrant, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(G), K)\\nImplies(Not(prolongs progression-free survival), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(H))\\nImplies(Not(improves outcomes), Not(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer))\\n--------\\nImplies(Not(K), F)\\nImplies(Not(patient is likely less sensitive to chemotherapy), beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(Not(K), J)\\nImplies(Not(patient is likely less sensitive to chemotherapy), improves outcomes)\\n--------\\nImplies(Not(I), K)\\nImplies(Not(benefit from treatment with alpelisib-fulvestrant), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(D), K)\\nImplies(Not(treatment with alpelisib\u2013fulvestrant), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(K), H)\\nImplies(Not(patient is likely less sensitive to chemotherapy), patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer)\\n--------\\nImplies(Not(H), K)\\nImplies(Not(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(K), Not(H))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer))\\n--------\\n'}",
            "9 iteration: {'syntactic validity': True, 'error code': '(* Explanation 5 states that patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who have previously received endocrine therapy benefit from treatment with alpelisib-fulvestrant. *)\\n(* This aligns with the logical relation Implies(H, F), which implies that such patients benefit from the treatment. *)\\n(* We can use this to infer the benefit of treatment with alpelisib-fulvestrant. *)\\nthen have \"Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 From e2 z \u2227 AlpelisibFulvestrant z \u2227 Targets e2 \u2227 PIK3CAMutation z\" sledgehammer', 'solving time': 103.19116830825806, 'proof tactics': [], 'code': 'theory clinical_64_9\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  PI3KAKTPathway :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  AlpelisibFulvestrant :: \"entity \u21d2 bool\"\\n  PIK3CAMutation :: \"entity \u21d2 bool\"\\n  Targets :: \"event \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  PIK3CAMutated :: \"entity \u21d2 bool\"\\n  HRPositive :: \"entity \u21d2 bool\"\\n  HER2Negative :: \"entity \u21d2 bool\"\\n  AdvancedBreastCancer :: \"entity \u21d2 bool\"\\n  Beneficial :: \"event \u21d2 bool\"\\n  For :: \"event \u21d2 entity \u21d2 bool\"\\n  EndocrineTherapy :: \"entity \u21d2 bool\"\\n  Received :: \"event \u21d2 bool\"\\n  Previously :: \"event \u21d2 bool\"\\n  Prolongs :: \"event \u21d2 bool\"\\n  ProgressionFreeSurvival :: \"event \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  From :: \"event \u21d2 entity \u21d2 bool\"\\n  Improves :: \"event \u21d2 bool\"\\n  Outcomes :: \"event \u21d2 bool\"\\n  Chemotherapy :: \"entity \u21d2 bool\"\\n  LessSensitiveTo :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 Mutations y \u2227 PI3KAKTPathway z \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Inhibit e2 \u2227 Agent e2 x \u2227 Proliferation y \u2227 Survival y\"\\n\\n(* Explanation 2: Treatment with alpelisib\u2013fulvestrant directly targets the PIK3CA mutation and is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it prolongs progression-free survival. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2 e3. Treatment x \u2227 AlpelisibFulvestrant x \u2227 PIK3CAMutation y \u2227 Targets e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Directly e1 \u2227 Patients z \u2227 PIK3CAMutated z \u2227 HRPositive z \u2227 HER2Negative z \u2227 AdvancedBreastCancer z \u2227 Beneficial e2 \u2227 For e2 z \u2227 EndocrineTherapy w \u2227 Received e3 \u2227 Agent e3 z \u2227 Patient e3 w \u2227 Previously e3 \u2227 Prolongs e2 \u2227 ProgressionFreeSurvival e2\"\\n\\n(* Explanation 3: Patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer benefit from treatment with alpelisib-fulvestrant, which targets the PIK3CA mutation and improves outcomes. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w e1 e2 e3. Patients x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1 \u2227 PIK3CAMutated x \u2227 HRPositive x \u2227 HER2Negative x \u2227 AdvancedBreastCancer x \u2227 Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 From e2 z \u2227 PIK3CAMutation w \u2227 Targets e3 \u2227 Agent e3 z \u2227 Patient e3 w \u2227 Improves e3 \u2227 Outcomes e3\"\\n\\n(* Explanation 4: Patient is likely less sensitive to chemotherapy. *)\\naxiomatization where\\n  explanation_4: \"\u2200x y. Patients x \u2227 Chemotherapy y \u27f6 LessSensitiveTo x y\"\\n\\n(* Explanation 5: Patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who have previously received endocrine therapy benefit from treatment with alpelisib-fulvestrant, as it targets the PIK3CA mutation and improves outcomes. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z w e1 e2 e3. Patients x \u2227 PIK3CAMutated x \u2227 HRPositive x \u2227 HER2Negative x \u2227 AdvancedBreastCancer x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1 \u2227 Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 From e2 z \u2227 PIK3CAMutation w \u2227 Targets e3 \u2227 Agent e3 z \u2227 Patient e3 w \u2227 Improves e3 \u2227 Outcomes e3\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patients x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1\"\\n  (* Hypothesis: If patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation *)\\n  shows \"\u2200x y z e1 e2. Patients x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1 \u27f6 (Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 From e2 z \u2227 AlpelisibFulvestrant z \u2227 Targets e2 \u2227 PIK3CAMutation z)\"\\nproof -\\n  (* From the premise, we have information about patients who have previously received endocrine therapy. *)\\n  from asm have \"Patients x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Previously e1\" <ATP>\\n  (* Explanation 5 states that patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who have previously received endocrine therapy benefit from treatment with alpelisib-fulvestrant. *)\\n  (* This aligns with the logical relation Implies(H, F), which implies that such patients benefit from the treatment. *)\\n  (* We can use this to infer the benefit of treatment with alpelisib-fulvestrant. *)\\n  then have \"Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 From e2 z \u2227 AlpelisibFulvestrant z \u2227 Targets e2 \u2227 PIK3CAMutation z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: using a kinase inhibitor (from Explanatory Sentence 1)\\nB: target mutations in the PI3K/AKT pathway (from Explanatory Sentence 1)\\nC: inhibit proliferation and survival (from Explanatory Sentence 1)\\nD: treatment with alpelisib\u2013fulvestrant (from Explanatory Sentence 2)\\nE: directly targets the PIK3CA mutation (from Explanatory Sentence 2)\\nF: beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously (from Explanatory Sentence 2)\\nG: prolongs progression-free survival (from Explanatory Sentence 2)\\nH: patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (from Explanatory Sentence 3)\\nI: improves outcomes (from Explanatory Sentence 3)\\nJ: patient is likely less sensitive to chemotherapy (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, And(B, C))\\nImplies(using a kinase inhibitor, B & C)\\n--------\\nImplies(D, And(E, F, G))\\nImplies(treatment with alpelisib\u2013fulvestrant, E & F & G)\\n--------\\nImplies(H, And(D, E, I))\\nImplies(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, D & E & I)\\n--------\\nJ\\npatient is likely less sensitive to chemotherapy\\n--------\\n\\nDerived Implications:\\nImplies(Not(J), I)\\nImplies(Not(patient is likely less sensitive to chemotherapy), improves outcomes)\\n--------\\nImplies(Not(G), Not(H))\\nImplies(Not(prolongs progression-free survival), Not(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer))\\n--------\\nImplies(D, G)\\nImplies(treatment with alpelisib\u2013fulvestrant, prolongs progression-free survival)\\n--------\\nImplies(Not(J), Not(B))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(target mutations in the PI3K/AKT pathway))\\n--------\\nImplies(Not(F), Not(D))\\nImplies(Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(Not(H), J)\\nImplies(Not(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(I), J)\\nImplies(Not(improves outcomes), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(D), J)\\nImplies(Not(treatment with alpelisib\u2013fulvestrant), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(I), Not(H))\\nImplies(Not(improves outcomes), Not(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer))\\n--------\\nImplies(Not(D), Not(H))\\nImplies(Not(treatment with alpelisib\u2013fulvestrant), Not(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer))\\n--------\\nImplies(H, E)\\nImplies(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, directly targets the PIK3CA mutation)\\n--------\\nImplies(H, F)\\nImplies(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(C, J)\\nImplies(inhibit proliferation and survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(B), J)\\nImplies(Not(target mutations in the PI3K/AKT pathway), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(H, J)\\nImplies(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(D))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(F, J)\\nImplies(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), G)\\nImplies(Not(patient is likely less sensitive to chemotherapy), prolongs progression-free survival)\\n--------\\nImplies(Not(E), Not(D))\\nImplies(Not(directly targets the PIK3CA mutation), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(H, D)\\nImplies(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, treatment with alpelisib\u2013fulvestrant)\\n--------\\nImplies(D, F)\\nImplies(treatment with alpelisib\u2013fulvestrant, beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(D, E)\\nImplies(treatment with alpelisib\u2013fulvestrant, directly targets the PIK3CA mutation)\\n--------\\nImplies(Not(J), Not(C))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(inhibit proliferation and survival))\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(target mutations in the PI3K/AKT pathway), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(J), B)\\nImplies(Not(patient is likely less sensitive to chemotherapy), target mutations in the PI3K/AKT pathway)\\n--------\\nImplies(Not(J), Not(I))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(improves outcomes))\\n--------\\nImplies(D, J)\\nImplies(treatment with alpelisib\u2013fulvestrant, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), C)\\nImplies(Not(patient is likely less sensitive to chemotherapy), inhibit proliferation and survival)\\n--------\\nImplies(A, B)\\nImplies(using a kinase inhibitor, target mutations in the PI3K/AKT pathway)\\n--------\\nImplies(Not(G), Not(D))\\nImplies(Not(prolongs progression-free survival), Not(treatment with alpelisib\u2013fulvestrant))\\n--------\\nImplies(Not(F), J)\\nImplies(Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), A)\\nImplies(Not(patient is likely less sensitive to chemotherapy), using a kinase inhibitor)\\n--------\\nImplies(H, I)\\nImplies(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, improves outcomes)\\n--------\\nImplies(Not(J), Not(F))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously))\\n--------\\nImplies(Not(F), Not(H))\\nImplies(Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously), Not(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer))\\n--------\\nImplies(Not(C), J)\\nImplies(Not(inhibit proliferation and survival), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(E, J)\\nImplies(directly targets the PIK3CA mutation, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(A), J)\\nImplies(Not(using a kinase inhibitor), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(A, C)\\nImplies(using a kinase inhibitor, inhibit proliferation and survival)\\n--------\\nImplies(G, J)\\nImplies(prolongs progression-free survival, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), E)\\nImplies(Not(patient is likely less sensitive to chemotherapy), directly targets the PIK3CA mutation)\\n--------\\nImplies(Not(J), F)\\nImplies(Not(patient is likely less sensitive to chemotherapy), beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(B, J)\\nImplies(target mutations in the PI3K/AKT pathway, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(inhibit proliferation and survival), Not(using a kinase inhibitor))\\n--------\\nImplies(H, G)\\nImplies(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, prolongs progression-free survival)\\n--------\\nImplies(Not(J), H)\\nImplies(Not(patient is likely less sensitive to chemotherapy), patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer)\\n--------\\nImplies(Not(E), J)\\nImplies(Not(directly targets the PIK3CA mutation), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(H))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer))\\n--------\\nImplies(Not(J), D)\\nImplies(Not(patient is likely less sensitive to chemotherapy), treatment with alpelisib\u2013fulvestrant)\\n--------\\nImplies(A, J)\\nImplies(using a kinase inhibitor, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(E), Not(H))\\nImplies(Not(directly targets the PIK3CA mutation), Not(patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer))\\n--------\\nImplies(Not(J), Not(E))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(directly targets the PIK3CA mutation))\\n--------\\nImplies(I, J)\\nImplies(improves outcomes, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(G), J)\\nImplies(Not(prolongs progression-free survival), patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(Not(J), Not(A))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(using a kinase inhibitor))\\n--------\\nImplies(Not(J), Not(G))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(prolongs progression-free survival))\\n--------\\n'}",
            "10 iteration: {'syntactic validity': True, 'error code': '(* Explanation 5 and 6 provide relevant information about the treatment with alpelisib-fulvestrant. *)\\n(* Explanation 5: Patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who have previously received endocrine therapy benefit from treatment with alpelisib-fulvestrant, as it targets the PIK3CA mutation and improves outcomes. *)\\n(* Explanation 6: Treatment with alpelisib-fulvestrant is specifically beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, as it directly targets the PIK3CA mutation and improves outcomes for those who have previously received endocrine therapy. *)\\n(* Logical relation: Implies(D, F) and Implies(D, E) *)\\n(* We can infer that if a patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target the PIK3CA mutation. *)\\nthen have \"Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 From e2 z \u2227 Target e2 \u2227 PIK3CAMutation z\" sledgehammer', 'solving time': 103.43230843544006, 'proof tactics': [], 'code': 'theory clinical_64_10\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  KinaseInhibitor :: \"entity \u21d2 bool\"\\n  Mutations :: \"entity \u21d2 bool\"\\n  PI3KAKTPathway :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Inhibit :: \"event \u21d2 bool\"\\n  Proliferation :: \"entity \u21d2 bool\"\\n  Survival :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  AlpelisibFulvestrant :: \"entity \u21d2 bool\"\\n  PIK3CAMutation :: \"entity \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  PIK3CAMutated :: \"entity \u21d2 bool\"\\n  HRPositive :: \"entity \u21d2 bool\"\\n  HER2Negative :: \"entity \u21d2 bool\"\\n  AdvancedBreastCancer :: \"entity \u21d2 bool\"\\n  EndocrineTherapy :: \"entity \u21d2 bool\"\\n  Targets :: \"event \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  Beneficial :: \"event \u21d2 bool\"\\n  Received :: \"event \u21d2 bool\"\\n  Previously :: \"event \u21d2 bool\"\\n  Prolongs :: \"event \u21d2 bool\"\\n  ProgressionFreeSurvival :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  From :: \"event \u21d2 entity \u21d2 bool\"\\n  Improves :: \"event \u21d2 bool\"\\n  Outcomes :: \"entity \u21d2 bool\"\\n  Chemotherapy :: \"entity \u21d2 bool\"\\n  LessSensitive :: \"entity \u21d2 entity \u21d2 bool\"\\n  Specifically :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. KinaseInhibitor x \u2227 Mutations y \u2227 PI3KAKTPathway z \u2227 Target e1 \u2227 Agent e1 x \u2227 Patient y \u2227 In y z \u2227 Inhibit e2 \u2227 Agent e2 x \u2227 Proliferation y \u2227 Survival y\"\\n\\n(* Explanation 2: Treatment with alpelisib\u2013fulvestrant directly targets the PIK3CA mutation and is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it prolongs progression-free survival. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2 e3. Treatment x \u2227 AlpelisibFulvestrant x \u2227 PIK3CAMutation y \u2227 Patients z \u2227 PIK3CAMutated z \u2227 HRPositive z \u2227 HER2Negative z \u2227 AdvancedBreastCancer z \u2227 EndocrineTherapy w \u2227 Targets e1 \u2227 Agent e1 x \u2227 Patient y \u2227 Directly e1 \u2227 Beneficial e2 \u2227 Agent e2 x \u2227 Patient z \u2227 Received e3 \u2227 Agent e3 z \u2227 Patient w \u2227 Previously e3 \u2227 Prolongs e3 \u2227 Agent e3 x \u2227 ProgressionFreeSurvival y\"\\n\\n(* Explanation 3: Patients who have previously received endocrine therapy and have PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer benefit from treatment with alpelisib-fulvestrant, which targets the PIK3CA mutation and improves outcomes. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w e1 e2 e3. Patients x \u2227 EndocrineTherapy y \u2227 PIK3CAMutated x \u2227 HRPositive x \u2227 HER2Negative x \u2227 AdvancedBreastCancer x \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 PIK3CAMutation w \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient y \u2227 Previously e1 \u2227 Benefit e2 \u2227 Agent e2 x \u2227 From e2 z \u2227 Targets e3 \u2227 Agent e3 z \u2227 Patient w \u2227 Improves e3 \u2227 Outcomes w\"\\n\\n(* Explanation 4: Patient is likely less sensitive to chemotherapy. *)\\naxiomatization where\\n  explanation_4: \"\u2200x y. Patient x \u2227 Chemotherapy y \u27f6 LessSensitive x y\"\\n\\n(* Explanation 5: Patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who have previously received endocrine therapy benefit from treatment with alpelisib-fulvestrant, as it targets the PIK3CA mutation and improves outcomes. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z w e1 e2 e3. Patients x \u2227 PIK3CAMutated x \u2227 HRPositive x \u2227 HER2Negative x \u2227 AdvancedBreastCancer x \u2227 EndocrineTherapy y \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 PIK3CAMutation w \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient y \u2227 Previously e1 \u2227 Benefit e2 \u2227 Agent e2 x \u2227 From e2 z \u2227 Targets e3 \u2227 Agent e3 z \u2227 Patient w \u2227 Improves e3 \u2227 Outcomes w\"\\n\\n(* Explanation 6: Treatment with alpelisib-fulvestrant is specifically beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, as it directly targets the PIK3CA mutation and improves outcomes for those who have previously received endocrine therapy. *)\\naxiomatization where\\n  explanation_6: \"\u2203x y z w e1 e2 e3. Treatment x \u2227 AlpelisibFulvestrant x \u2227 Patients y \u2227 PIK3CAMutated y \u2227 HRPositive y \u2227 HER2Negative y \u2227 AdvancedBreastCancer y \u2227 PIK3CAMutation z \u2227 EndocrineTherapy w \u2227 Beneficial e1 \u2227 Agent e1 x \u2227 Patient y \u2227 Specifically e1 \u2227 Targets e2 \u2227 Agent e2 x \u2227 Patient z \u2227 Directly e2 \u2227 Improves e3 \u2227 Agent e3 x \u2227 Outcomes z \u2227 Received e3 \u2227 Agent e3 y \u2227 Patient w \u2227 Previously e3\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient y \u2227 Previously e1\"\\n  (* Hypothesis: If patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)\\n  shows \"\u2200x y z e1 e2. (Patient x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient y \u2227 Previously e1) \u27f6 (Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 From e2 z \u2227 Target e2 \u2227 PIK3CAMutation z)\"\\nproof -\\n  (* From the premise, we have information about the patient and their previous endocrine therapy. *)\\n  from asm have \"Patient x \u2227 EndocrineTherapy y \u2227 Received e1 \u2227 Agent e1 x \u2227 Patient y \u2227 Previously e1\" <ATP>\\n  (* Explanation 5 and 6 provide relevant information about the treatment with alpelisib-fulvestrant. *)\\n  (* Explanation 5: Patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who have previously received endocrine therapy benefit from treatment with alpelisib-fulvestrant, as it targets the PIK3CA mutation and improves outcomes. *)\\n  (* Explanation 6: Treatment with alpelisib-fulvestrant is specifically beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, as it directly targets the PIK3CA mutation and improves outcomes for those who have previously received endocrine therapy. *)\\n  (* Logical relation: Implies(D, F) and Implies(D, E) *)\\n  (* We can infer that if a patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target the PIK3CA mutation. *)\\n  then have \"Benefit e2 \u2227 Agent e2 x \u2227 Treatment z \u2227 AlpelisibFulvestrant z \u2227 From e2 z \u2227 Target e2 \u2227 PIK3CAMutation z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: using a kinase inhibitor (from Explanatory Sentence 1)\\nB: target mutations in the PI3K/AKT pathway (from Explanatory Sentence 1)\\nC: inhibit proliferation and survival (from Explanatory Sentence 1)\\nD: treatment with alpelisib-fulvestrant (from Explanatory Sentences 2, 3, 5, 6)\\nE: directly targets the PIK3CA mutation (from Explanatory Sentences 2, 3, 5, 6)\\nF: beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously (from Explanatory Sentences 2, 3, 5, 6)\\nG: prolongs progression-free survival (from Explanatory Sentence 2)\\nH: improves outcomes (from Explanatory Sentences 3, 5, 6)\\nI: patient is likely less sensitive to chemotherapy (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, And(B, C))\\nImplies(using a kinase inhibitor, B & C)\\n--------\\nImplies(D, And(E, F, G))\\nImplies(treatment with alpelisib-fulvestrant, E & F & G)\\n--------\\nImplies(D, And(E, F, H))\\nImplies(treatment with alpelisib-fulvestrant, E & F & H)\\n--------\\nImplies(F, I)\\nImplies(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is likely less sensitive to chemotherapy)\\n--------\\n\\nDerived Implications:\\nImplies(D, G)\\nImplies(treatment with alpelisib-fulvestrant, prolongs progression-free survival)\\n--------\\nImplies(Not(G), Not(D))\\nImplies(Not(prolongs progression-free survival), Not(treatment with alpelisib-fulvestrant))\\n--------\\nImplies(Not(F), Not(D))\\nImplies(Not(beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously), Not(treatment with alpelisib-fulvestrant))\\n--------\\nImplies(D, I)\\nImplies(treatment with alpelisib-fulvestrant, patient is likely less sensitive to chemotherapy)\\n--------\\nImplies(A, C)\\nImplies(using a kinase inhibitor, inhibit proliferation and survival)\\n--------\\nImplies(Not(I), Not(D))\\nImplies(Not(patient is likely less sensitive to chemotherapy), Not(treatment with alpelisib-fulvestrant))\\n--------\\nImplies(D, E)\\nImplies(treatment with alpelisib-fulvestrant, directly targets the PIK3CA mutation)\\n--------\\nImplies(D, F)\\nImplies(treatment with alpelisib-fulvestrant, beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously)\\n--------\\nImplies(Not(E), Not(D))\\nImplies(Not(directly targets the PIK3CA mutation), Not(treatment with alpelisib-fulvestrant))\\n--------\\nImplies(Not(H), Not(D))\\nImplies(Not(improves outcomes), Not(treatment with alpelisib-fulvestrant))\\n--------\\nImplies(A, B)\\nImplies(using a kinase inhibitor, target mutations in the PI3K/AKT pathway)\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(target mutations in the PI3K/AKT pathway), Not(using a kinase inhibitor))\\n--------\\nImplies(D, H)\\nImplies(treatment with alpelisib-fulvestrant, improves outcomes)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(inhibit proliferation and survival), Not(using a kinase inhibitor))\\n--------\\n'}"
        ]
    }
}